Professor Richard Lock

Lock RB; Szymanska B; Carol H; Lock RB, 2011, 'Preclinical Evaluation', in Saha V; Kearns P (ed.), New Agents for the Treatment of Acute Lymphoblastic Leukemia, Springer, New York, Dordrecht, Heidelberg, London, pp. 39 - 60, http://dx.doi.org/10.1007/978-1-4419-8459-3_3

Smith M; Meenakshi D; Wheatley K; Lock RB; Hunsberger S, 2011, 'Strategies for New Agent Development and Clinical Trial Considerations', in Reaman GH; Smith FO (ed.), Childhood Leukemia, edn. Pediatric Oncology, Springer-Verlag, Berlin, pp. 215 - 241, http://dx.doi.org/10.1007/978-3-642-13781-5_8

Lock RB; Liem NL; Papa RA, 2005, 'Preclinical testing of antileukemic drugs using an in vivo model of systemic disease', in Blumenthal ED (ed.), Methods in Molecular Medicine: Vol 2: In Vivo Models, Imaging and Molecular Regulators, pp. 323 - 334

Lock RB; Murphy K, 2005, 'Immunodetecting members of the Bcl-2 family of proteins', in Blumenthal RD (ed.), Methods in Molecular Medicine, vol III: Chemosensitivity: Vol 2, Humana Press, Totowa NJ, pp. 83 - 96

Lock RB; Murphy KM, 2005, 'Immunodetecting members of the Bcl-2 family of proteins.', in Blumenthal RD (ed.), Methods in Molecular Medicine, Vol2: In Vivo Models, Imaging, and Molecular Regulators, pp. 83 - 96

Lock RB; Papa R; Liem N, 2005, 'Preclinical Testing of Antileukemic Drugs Using an In Vivo Model of Systemic Disease', in Blumenthal RD (ed.), Methods in Molecular Medicine, vol III: Chemosensitivity: Vol 2, Humana Press, Totowa, NJ, pp. 323 - 334, http://dx.doi.org/10.1385/1-59259-889-7:323

Lock RB, 1994, 'Determinants of etoposide cytotoxicity in vitro', in Valeriote FA; Corbett TH; Baker LH (ed.), Anticancer Drug Discovery and Development, Kluwer Academic Publishers, Boston, pp. 347 - 363

Whelan RDH; Hosking LK; Shellard SA; Lock RB; Hill BT, 1990, 'The differential expression of resistance to etoposide, vincristine, Adriamycin and Novantrone in human tumour cell lines in vitro: "typical" and "atypical" multidrug resistance', in Osieka R; Seeber S; Enghofer E (ed.), Chemotherapieresistenz, De Gruyter, pp. 41 - 50, http://dx.doi.org/10.1515/9783110857689-005

Hill BT; Lock RB, 1989, 'Tumor cell resistance to etoposide (VP-16) - A review', in Resistance to Antineoplastic Drugs, CRC Press, Boca Raton, Florida, pp. 185 - 205

Hill BT; Whelan RDH; Hosking LK; Lock RB, 1989, 'Investigations of antitumour drug resistance using human tumour cell lines in vitro', in Ghione M; Ramsa L (ed.), Resistance to Antitumor Agents, Harwood Academic Press, London, pp. 62 - 71

Ross WE; Lock RB; Chow KC; Latham M; Sullivan D, 1989, 'Pathways of resistance to topoisomerase II inhibitors', in Tapiero H; Robert J; Lampidis TJ (ed.), Anticancer Drugs, Colloque INSERM/John Libbey Eurotext Ltd, pp. 93 - 101

Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS, 2022, 'Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy', Leukemia, pp. 1 - 11, http://dx.doi.org/10.1038/s41375-022-01746-3

Doculara L; Trahair TN; Bayat N; Lock RB, 2022, 'Circulating Tumor DNA in Pediatric Cancer', Frontiers in Molecular Biosciences, vol. 9, http://dx.doi.org/10.3389/fmolb.2022.885597

Lau LMS; Mayoh C; Xie J; Barahona P; MacKenzie KL; Wong M; Kamili A; Tsoli M; Failes TW; Kumar A; Mould EVA; Gifford A; Chow SO; Pinese M; Fletcher JI; Arndt GM; Khuong-Quang DA; Wadham C; Batey D; Eden G; Trebilcock P; Joshi S; Alfred S; Gopalakrishnan A; Khan A; Grebert Wade D; Strong PA; Manouvrier E; Morgan LT; Span M; Lim JY; Cadiz R; Ung C; Thomas DM; Tucker KM; Warby M; McCowage GB; Dalla-Pozza L; Byrne JA; Saletta F; Fellowes A; Fox SB; Norris MD; Tyrrell V; Trahair TN; Lock RB; Cowley MJ; Ekert PG; Haber M; Ziegler DS; Marshall GM, 2022, 'In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer', EMBO Molecular Medicine, vol. 14, http://dx.doi.org/10.15252/emmm.202114608

Lock RB; Evans K; Randall J; Erickson SW; Earley EJ; Neuhauser S; Stearns T; Philip V; Teicher BA; Watkins K; Sloss CM; Zweidler-McKay PA; Smith MA, 2022, 'Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia', Blood, vol. 140, pp. 8983 - 8984, http://dx.doi.org/10.1182/blood-2022-159867

Lock RB; Evans K; Watts B; Randall J; Toscan CE; Earley EJ; Erickson SW; Belmontes B; Wong P; Teicher BA; Hughes PE; Smith MA, 2022, 'Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia', Blood, vol. 140, pp. 11690 - 11691, http://dx.doi.org/10.1182/blood-2022-159885

Mesbahi Y; Trahair TN; Lock RB; Connerty P, 2022, 'Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells', Frontiers in Oncology, vol. 12, http://dx.doi.org/10.3389/fonc.2022.807266

Pearson HCL; Hunt KV; Trahair TN; Lock RB; Lee HJ; De Bock CE, 2022, 'The Promise of Single-cell Technology in Providing New Insights into the Molecular Heterogeneity and Management of Acute Lymphoblastic Leukemia', HemaSphere, vol. 6, pp. E734, http://dx.doi.org/10.1097/HS9.0000000000000734

Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K, 2022, 'The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression', Frontiers in Oncology, vol. 12, http://dx.doi.org/10.3389/fonc.2022.863329

Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB, 2021, 'Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia', Leukemia, vol. 35, pp. 3101 - 3112, http://dx.doi.org/10.1038/s41375-021-01248-8

Connerty P; Moles E; de Bock CE; Jayatilleke N; Smith JL; Meshinchi S; Mayoh C; Kavallaris M; Lock RB, 2021, 'Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for t(8;21) pediatric acute myeloid leukemia', Pharmaceutics, vol. 13, pp. 1681 - 1681, http://dx.doi.org/10.3390/pharmaceutics13101681

Di Grande A; Peirs S; Donovan PD; Van Trimpont M; Morscio J; Lintermans B; Reunes L; Vandamme N; Goossens S; Nguyen HA; Lavie A; Lock RB; Prehn JHM; Van Vlierberghe P; Ní Chonghaile T, 2021, 'The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL.', Blood Advances, vol. 5, pp. 1963 - 1976, http://dx.doi.org/10.1182/bloodadvances.2021004177

Karsa M; Kosciolek A; Bongers A; Mariana A; Failes T; Gifford AJ; Kees UR; Cheung LC; Kotecha RS; Arndt GM; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ; Somers K, 2021, 'Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin', British Journal of Cancer, vol. 125, pp. 55 - 64, http://dx.doi.org/10.1038/s41416-021-01332-x

Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupere-Richer D; Roth JS; Jing D; Casellas Roman HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD, 2021, 'PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia.', Cancer Discov, pp. 1 - 46, http://dx.doi.org/10.1158/2159-8290.CD-20-1771

Matthijssens F; Sharma ND; Nysus M; Nickl CK; Kang H; Perez DR; Lintermans B; Van Loocke W; Roels J; Peirs S; Demoen L; Pieters T; Reunes L; Lammens T; De Moerloose B; Van Nieuwerburgh F; Deforce DL; Cheung LC; Kotecha RS; Risseeuw MDP; Van Calenbergh S; Takarada T; Yoneda Y; Van Delft FW; Lock RB; Merkley SD; Chigaev A; Sklar LA; Mullighan CG; Loh ML; Winter SS; Hunger SP; Goossens S; Castillo EF; Ornatowski W; Van Vlierberghe P; Matlawska-Wasowska K, 2021, 'RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia', Journal of Clinical Investigation, vol. 131, http://dx.doi.org/10.1172/JCI141566

Mohamed SMA; Wohlmann A; Schofield P; Sia KCS; McCalmont H; Savvides SN; Verstraete K; Kavallaris M; Christ D; Friedrich KH; Bayat N; Lock RB, 2021, 'A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia', International Journal of Biological Macromolecules, vol. 190, pp. 214 - 223, http://dx.doi.org/10.1016/j.ijbiomac.2021.08.194

Murray HC; Enjeti AK; Kahl RGS; Flanagan HM; Sillar J; Skerrett-Byrne DA; Al Mazi JG; Au GG; de Bock CE; Evans K; Smith ND; Anderson A; Nixon B; Lock RB; Larsen MR; Verrills NM; Dun MD, 2021, 'Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia', Leukemia, vol. 35, pp. 1782 - 1787, http://dx.doi.org/10.1038/s41375-020-01050-y

Tremblay CS; Chiu SK; Saw J; McCalmont H; Litalien V; Boyle J; Sonderegger SE; Chau N; Evans K; Cerruti L; Salmon JM; McCluskey A; Lock RB; Robinson PJ; Jane SM; Curtis DJ, 2021, 'Author Correction: Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells (Nature Communications, (2020), 11, 1, (6211), 10.1038/s41467-020-20091-6)', Nature Communications, vol. 12, pp. 1288, http://dx.doi.org/10.1038/s41467-021-21688-1

Van Thillo Q; De Bie J; Seneviratne JA; Demeyer S; Omari S; Balachandran A; Zhai V; Tam WL; Sweron B; Geerdens E; Gielen O; Provost S; Segers H; Boeckx N; Marshall GM; Cheung BB; Isobe K; Kato I; Takita J; Amos TG; Deveson IW; McCalmont H; Lock RB; Oxley EP; Garwood MM; Dickins RA; Uyttebroeck A; Carter DR; Cools J; de Bock CE, 2021, 'Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia', Nature Communications, vol. 12, pp. 4164, http://dx.doi.org/10.1038/s41467-021-24442-9

Xie J; Kumar A; Dolman MEM; Mayoh C; Khuong-Quang DA; Cadiz R; Wong-Erasmus M; Mould EVA; Grebert-Wade D; Barahona P; Kamili A; Tsoli M; Failes TW; Chow SO; Bhatia K; Marshall GM; Ziegler DS; Haber M; Lock RB; Tyrrell V; Lau L; Athanasatos P; Gifford AJ, 2021, 'The important role of routine cytopathology in pediatric precision oncology', Cancer Cytopathology, http://dx.doi.org/10.1002/cncy.22448

Alruwetei AM; Bendak K; Yadav BD; Carol H; Evans K; Mayoh C; Sutton R; Marshall GM; Lock RB, 2020, 'Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia', British Journal of Cancer, vol. 123, pp. 742 - 751, http://dx.doi.org/10.1038/s41416-020-0933-4

Connerty P; Lock RB; de Bock CE, 2020, 'Long Non-coding RNAs: Major Regulators of Cell Stress in Cancer', Frontiers in Oncology, vol. 10, http://dx.doi.org/10.3389/fonc.2020.00285

Korotchkina L; Kazyulkin D; Komarov PG; Polinsky A; Andrianova EL; Joshi S; Gupta M; Vujcic S; Kononov E; Toshkov I; Tian Y; Krasnov P; Chernov MV; Veith J; Antoch MP; Middlemiss S; Somers K; Lock RB; Norris MD; Henderson MJ; Haber M; Chernova OB; Gudkov AV, 2020, 'OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis', Leukemia, vol. 34, pp. 1828 - 1839, http://dx.doi.org/10.1038/s41375-019-0692-5

Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR, 2020, 'PIM kinase inhibitors block the growth of primary T-cell acute lymphoblastic leukemia: Resistance pathways identified by network modeling analysis', Molecular Cancer Therapeutics, vol. 19, pp. 1809 - 1821, http://dx.doi.org/10.1158/1535-7163.MCT-20-0160

McCalmont H; Li KL; Jones L; Toubia J; Bray SC; Casolari DA; Mayoh C; Samaraweera SE; Lewis ID; Prinjha RK; Smithers N; Wang S; Lock RB; D’Andrea RJ, 2020, 'Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia', Blood Advances, vol. 4, pp. 296 - 300, http://dx.doi.org/10.1182/bloodadvances.2019000586

Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB, 2020, 'Targeting TSLP-induced tyrosine kinase signaling pathways in CRLF2-Rearranged Ph-like ALL', Molecular Cancer Research, vol. 18, pp. 1767 - 1776, http://dx.doi.org/10.1158/1541-7786.MCR-19-1098

Somers K; Evans K; Cheung L; Karsa M; Pritchard T; Kosciolek A; Bongers A; El-Ayoubi A; Forgham H; Middlemiss S; Mayoh C; Jones L; Gupta M; Kees UR; Chernova O; Korotchkina L; Gudkov AV; Erickson SW; Teicher B; Smith MA; Norris MD; Haber M; Lock RB; Henderson MJ, 2020, 'Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia', Leukemia, vol. 34, pp. 1524 - 1539, http://dx.doi.org/10.1038/s41375-019-0683-6

Toscan CE; Jing D; Mayoh C; Lock RB, 2020, 'Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression', British Journal of Cancer, vol. 122, pp. 1769 - 1781, http://dx.doi.org/10.1038/s41416-020-0824-8

Tremblay CS; Chiu SK; Saw J; McCalmont H; Litalien V; Boyle J; Sonderegger SE; Chau N; Evans K; Cerruti L; Salmon JM; McCluskey A; Lock RB; Robinson PJ; Jane SM; Curtis DJ, 2020, 'Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells', Nature Communications, vol. 11, http://dx.doi.org/10.1038/s41467-020-20091-6

Wong M; Mayoh C; Lau LMS; Khuong-Quang DA; Pinese M; Kumar A; Barahona P; Wilkie EE; Sullivan P; Bowen-James R; Syed M; Martincorena I; Abascal F; Sherstyuk A; Bolanos NA; Baber J; Priestley P; Dolman MEM; Fleuren EDG; Gauthier ME; Mould EVA; Gayevskiy V; Gifford AJ; Grebert-Wade D; Strong PA; Manouvrier E; Warby M; Thomas DM; Kirk J; Tucker K; O’Brien T; Alvaro F; McCowage GB; Dalla-Pozza L; Gottardo NG; Tapp H; Wood P; Khaw SL; Hansford JR; Moore AS; Norris MD; Trahair TN; Lock RB; Tyrrell V; Haber M; Marshall GM; Ziegler DS; Ekert PG; Cowley MJ, 2020, 'Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer', Nature Medicine, vol. 26, pp. 1742 - 1753, http://dx.doi.org/10.1038/s41591-020-1072-4

Xie J; Span M; van Maarseveen E; Langenhorst J; Boddy AV; Sia KCS; Sutton R; Venn N; Punt AM; Tyrrell V; Haber M; Trahair T; Lau L; Marshall GM; Lock RB, 2020, 'Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia', Pediatric Blood and Cancer, vol. 67, pp. e28133, http://dx.doi.org/10.1002/pbc.28133

Bayat N; McOrist N; Ariotti N; Lai M; Sia KCS; Li Y; Grace JL; Quinn JF; Whittaker MR; Kavallaris M; Davis TP; Lock RB, 2019, 'Thiol-reactive star polymers functionalized with short ethoxy-containing moieties exhibit enhanced uptake in acute lymphoblastic leukemia cells', International Journal of Nanomedicine, vol. 14, pp. 9795 - 9808, http://dx.doi.org/10.2147/IJN.S220326

Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua G-A; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS, 2019, 'Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.', Haematologica, http://dx.doi.org/10.3324/haematol.2018.192906

Evans K; Duan JX; Pritchard T; Jones CD; McDermott L; Gu Z; Toscan CE; El-Zein N; Mayoh C; Erickson SW; Guo Y; Meng F; Jung D; Rathi KS; Roberts KG; Mullighan CG; Shia CS; Pearce T; Teicher BA; Smith MA; Lock RB, 2019, 'OBI-3424, a novel AKR1c3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL', Clinical Cancer Research, vol. 25, pp. 4493 - 4503, http://dx.doi.org/10.1158/1078-0432.CCR-19-0551

Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB, 2019, 'Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts', Pediatric Blood and Cancer, vol. 66, pp. e27765, http://dx.doi.org/10.1002/pbc.27765

Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA, 2019, 'A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia', Cancer Cell, vol. 36, pp. 660 - 673.e11, http://dx.doi.org/10.1016/j.ccell.2019.11.001

Mosse YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ, 2019, 'A phase II study of alisertib in children with recurrent/refractory solid tumors or leukemia: Children's Oncology Group Phase I and pilot Consortium (ADVL0921)', Clinical Cancer Research, vol. 25, pp. 3229 - 3238, http://dx.doi.org/10.1158/1078-0432.CCR-18-2675

Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Egolf LE; Way GP; Farrel A; Kendsersky NM; Patel K; Gaonkar KS; Modi A; Berko ER; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni HV; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li XN; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM, 2019, 'Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design', Cell Reports, vol. 29, pp. 1675 - 1689.e9, http://dx.doi.org/10.1016/j.celrep.2019.09.071

Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ, 2019, 'Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia', International Journal of Cancer, http://dx.doi.org/10.1002/ijc.32582

de Bock CE; Down M; Baidya K; Sweron B; Boyd AW; Fiers M; Burns GF; Molloy TJ; Lock RB; Soulier J; Taghon T; Van Vlierberghe P; Cools J; Holst J; Thorne RF, 2019, 'T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development', Haematologica, vol. 104, pp. e204 - e207, http://dx.doi.org/10.3324/haematol.2018.198424

Jing D; Huang Y; Liu X; Sia KCS; Zhang JC; Tai X; Wang M; Toscan CE; McCalmont H; Evans K; Mayoh C; Poulos RC; Span M; Mi J; Zhang C; Wong JWH; Beck D; Pimanda JE; Lock RB, 2018, 'Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia', Cancer Cell, vol. 34, pp. 906 - 921.e8, http://dx.doi.org/10.1016/j.ccell.2018.11.002

McClure BJ; Heatley SL; Kok CH; Sadras T; An J; Hughes TP; Lock RB; Yeung D; Sutton R; White DL, 2018, 'Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression', British Journal of Cancer, vol. 118, pp. 1000 - 1004, http://dx.doi.org/10.1038/s41416-018-0022-0

Somers K; Evans K; Cheung L; Korotchkina L; Chernova O; Gudkov A; Norris M; Haber M; Lock R; Henderson M, 2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', ESMO Open, vol. 3, pp. A238 - A238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563

Wakefield CE; Doolan EL; Fardell JE; Signorelli C; Quinn VF; Tucker KF; Patenaude AF; Marshall GM; Lock RB; Georgiou G; Cohn RJ, 2018, 'Protocol for the avatar acceptability study: A multiperspective cross-sectional study evaluating the acceptability of using patient-derived xenografts to guide personalised cancer care in Australia and New Zealand', BMJ Open, vol. 8, http://dx.doi.org/10.1136/bmjopen-2018-024064

Wakefield CE; Doolan EL; Fardell JE; Signorelli C; Quinn VF; Tucker KM; Patenaude AF; Marshall GM; Lock RB; Georgiou G; Cohn RJ, 2018, 'The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care', EBioMedicine, vol. 37, pp. 205 - 213, http://dx.doi.org/10.1016/j.ebiom.2018.10.060

Brumatti G; Ma C; Lalaoui N; Nguyen N-Y; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J, 2017, 'The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia (vol 8, 339ra69, 2016)', SCIENCE TRANSLATIONAL MEDICINE, vol. 9, http://dx.doi.org/10.1126/scitranslmed.aan8181

Jones L; Richmond J; Evans K; Carol H; Jing D; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB, 2017, 'Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL', Clinical Cancer Research, vol. 23, pp. 3744 - 3755, http://dx.doi.org/10.1158/1078-0432.CCR-16-2392

Kurmasheva RT; Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Kang M; Reynolds CP; Wu J; Houghton PJ; Smith MA, 2017, 'Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 64, http://dx.doi.org/10.1002/pbc.26304

Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA, 2017, 'Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 64, http://dx.doi.org/10.1002/pbc.26263

Nilsson S; Cao B; Leung WY; Williams B; Hatwell-Humble J; Domingues M; Jones L; Bendall L; Lock R, 2017, 'Therapeutic targeting of a9b1 and a4b1 integrins for chemosensitization of drug resistant acute leukaemia', Experimental Hematology, vol. 53, pp. S75 - S75, http://dx.doi.org/10.1016/j.exphem.2017.06.158

Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 63, pp. 276 - 286, http://dx.doi.org/10.1002/pbc.25727

Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW, 2016, 'The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid Leukemia', Cancer Research, vol. 76, pp. 1158 - 1169, http://dx.doi.org/10.1158/0008-5472.CAN-15-1070

Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; De Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J, 2016, 'The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia', Science Translational Medicine, vol. 8, http://dx.doi.org/10.1126/scitranslmed.aad3099

Churchman ML; Evans K; Richmond J; Robbins A; Jones L; Shapiro IM; Pachter JA; Weaver DT; Houghton PJ; Smith MA; Lock RB; Mullighan CG, 2016, 'Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL', JCI Insight, vol. 1, http://dx.doi.org/10.1172/jci.insight.86082

Dolai S; Sia KCS; Robbins AK; Zhong L; Heatley SL; Vincent TL; Hochgräfe F; Sutton R; Kurmasheva RT; Revesz T; White DL; Houghton PJ; Smith MA; Teachey DT; Daly RJ; Raftery MJ; Lock RB, 2016, 'Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia', Cancer Research, vol. 76, pp. 2766 - 2777, http://dx.doi.org/10.1158/0008-5472.CAN-15-2786

El-Hoss J; Jing D; Evans K; Toscan C; Xie J; Lee H; Taylor RA; Lawrence MG; Risbridger GP; MacKenzie KL; Sutton R; Lock RB, 2016, 'A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts', Oncotarget, vol. 7, pp. 60475 - 60490, http://dx.doi.org/10.18632/oncotarget.11125

Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Reynolds CP; Kang MH; Billups CA; Collins J; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 63, pp. 443 - 450, http://dx.doi.org/10.1002/pbc.25826

Huang Y; Thoms JAI; Tursky ML; Knezevic K; Beck D; Chandrakanthan V; Suryani S; Olivier J; Boulton A; Glaros EN; Thomas SR; Lock RB; MacKenzie KL; Bushweller JH; Wong JWH; Pimanda JE, 2016, 'MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation', Leukemia, vol. 30, pp. 1552 - 1561, http://dx.doi.org/10.1038/leu.2016.55

Jones L; Carol H; Evans K; Richmond J; Houghton PJ; Smith MA; Lock RB, 2016, 'A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program', Leukemia, vol. 30, pp. 2133 - 2141, http://dx.doi.org/10.1038/leu.2016.192

Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, http://dx.doi.org/10.1002/pbc.26064

Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing (Stage 1) of MK-8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 63, pp. 1744 - 1752, http://dx.doi.org/10.1002/pbc.26064

Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DCS; Lock RB, 2016, 'Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia', Blood, vol. 128, pp. 1382 - 1395, http://dx.doi.org/10.1182/blood-2016-03-707414

Lalaoui N; Hänggi K; Brumatti G; Chau D; Nguyen NYN; Vasilikos L; Spilgies LM; Heckmann DA; Ma C; Ghisi M; Salmon JM; Matthews GM; de Valle E; Moujalled DM; Menon MB; Spall SK; Glaser SP; Richmond J; Lock RB; Condon SM; Gugasyan R; Gaestel M; Guthridge M; Johnstone RW; Munoz L; Wei A; Ekert PG; Vaux DL; Wong WWL; Silke J, 2016, 'Correction: Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics (Cancer Cell (2016) 30(3) (499–500) (S1535610816000350) (10.1016/j.ccell.2016.01.006))', Cancer Cell, vol. 30, pp. 499 - 500, http://dx.doi.org/10.1016/j.ccell.2016.08.009

Lalaoui N; Hänggi K; Brumatti G; Chau D; Nguyen NYN; Vasilikos L; Spilgies LM; Heckmann DA; Ma C; Ghisi M; Salmon JM; Matthews GM; de Valle E; Moujalled DM; Menon MB; Spall SK; Glaser SP; Richmond J; Lock RB; Condon SM; Gugasyan R; Gaestel M; Guthridge M; Johnstone RW; Munoz L; Wei A; Ekert PG; Vaux DL; Wong WWL; Silke J, 2016, 'Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics', Cancer Cell, vol. 29, pp. 145 - 158, http://dx.doi.org/10.1016/j.ccell.2016.01.006

Murphy B; Yin H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Kurmasheva RT; Dvorchik I; Wu J; Billups CA; Boateng N; Smith MA; Lock RB; Houghton PJ, 2016, 'Evaluation of alternative in vivo drug screening methodology: A single mouse analysis', Cancer Research, vol. 76, pp. 5798 - 5809, http://dx.doi.org/10.1158/0008-5472.CAN-16-0122

Richmond J; Robbins A; Evans K; Beck D; Kurmasheva RT; Billups CA; Carol H; Heatley S; Sutton R; Marshall GM; White D; Pimanda J; Houghton PJ; Smith MA; Lock RB, 2016, 'Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant', Cancer Research, vol. 76, pp. 4579 - 4591, http://dx.doi.org/10.1158/0008-5472.CAN-16-0523

Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T, 2016, 'The bromodomain inhibitor jq1 and the histone deacetylase inhibitor panobinostat synergistically reduce n-myc expression and induce anticancer effects', Clinical Cancer Research, vol. 22, pp. 2534 - 2544, http://dx.doi.org/10.1158/1078-0432.CCR-15-1666

Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM, 2016, 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors', Oncotarget, vol. 7, pp. 47465 - 47478, http://dx.doi.org/10.18632/oncotarget.10167

Trahair TN; Lock RB; Sutton R; Sia KCS; Evans K; Richmond J; Law T; Venn NC; Irving JA; Moore S; Nievergall E; Dang P; Heatley SL; White DL; Revesz T, 2016, 'Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL', Bone Marrow Transplantation, vol. 51, pp. 1279 - 1282, http://dx.doi.org/10.1038/bmt.2016.122

Yadav BD; Samuels AL; Wells JE; Sutton R; Venn NC; Bendak K; Anderson D; Marshall GM; Cole CH; Beesley AH; Kees UR; Lock RB, 2016, 'Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia', Oncotarget, vol. 7, pp. 58728 - 58742, http://dx.doi.org/10.18632/oncotarget.11233

Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2015, 'Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program', Pediatric Blood and Cancer, http://dx.doi.org/10.1002/pbc.25727

Carol H; Fan MMY; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB, 2015, 'Efficacy of CPX-351, (cytarabine: DAunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 62, pp. 65 - 71, http://dx.doi.org/10.1002/pbc.25133

Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB, 2015, 'P21^WAF1 modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia', Cell Cycle, vol. 14, pp. 3602 - 3612, http://dx.doi.org/10.1080/15384101.2015.1100774

Dolai S, 2015, 'Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia', Blood, vol. 125, pp. 1759 - 1767, http://dx.doi.org/10.1182/blood-2014-06-580480

Goossens S; Radaelli E; Blanchet O; Durinck K; Van Der Meulen J; Peirs S; Taghon T; Tremblay CS; Costa M; Ghahremani MF; De Medts J; Bartunkova S; Haigh K; Schwab C; Farla N; Pieters T; Matthijssens F; Van Roy N; Best JA; Deswarte K; Bogaert P; Carmichael C; Rickard A; Suryani S; Bracken LS; Alserihi R; Canté-Barrett K; Haenebalcke L; Clappier E; Rondou P; Slowicka K; Huylebroeck D; Goldrath AW; Janzen V; McCormack MP; Lock RB; Curtis DJ; Harrison C; Berx G; Speleman F; Meijerink JPP; Soulier J; Van Vlierberghe P; Haigh JJ, 2015, 'ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling', Nature Communications, vol. 6, http://dx.doi.org/10.1038/ncomms6794

Jing RBAB, 2015, 'Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells', Blood, vol. 125, pp. 273 - 283, http://dx.doi.org/10.1182/blood-2014-05-576470

Kolb EA; Gorlick R; Keir ST; Maris JM; Kang MH; Reynolds CP; Lock RB; Carol H; Wu J; Kurmasheva RT; Houghton PJ; Smith MA, 2015, 'Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 62, pp. 1106 - 1109, http://dx.doi.org/10.1002/pbc.25329

Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; We A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB, 2015, 'Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice', Haematologica, vol. 100, pp. 914 - 926, http://dx.doi.org/10.3324/haematol.2014.113092

Manesh DM; El-Hoss J; Evans K; Richmond J; Toscan CE; Bracken LS; Hedrick A; Sutton R; Marshall GM; Wilson WR; Kurmasheva RT; Billups C; Houghton PJ; Smith MA; Carol H; Lock RB, 2015, 'AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia', Blood, vol. 126, pp. 1193 - 1202, http://dx.doi.org/10.1182/blood-2014-12-618900

Nowak D; Liem NLM; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP, 2015, 'Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance', Experimental Hematology, vol. 43, pp. 32 - 43, http://dx.doi.org/10.1016/j.exphem.2014.09.007

Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB, 2015, 'Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia', Clinical Cancer Research, vol. 21, pp. 1395 - 1405, http://dx.doi.org/10.1158/1078-0432.CCR-14-2300

Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ, 2015, 'Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673', Pediatric Blood and Cancer, vol. 62, pp. 91 - 98, http://dx.doi.org/10.1002/pbc.25201

Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ, 2015, 'Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program', Clinical Cancer Research, vol. 21, pp. 819 - 832, http://dx.doi.org/10.1158/1078-0432.CCR-14-2572

Suryani S; Bracken LS; Harvey RC; Sia KCS; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB, 2015, 'Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia', Molecular Cancer Therapeutics, vol. 14, pp. 364 - 374, http://dx.doi.org/10.1158/1535-7163.MCT-14-0647

Toscan CE; Rahimi M; Bhadbhade M; Pickford R; McAlpine SR; Lock RB, 2015, 'Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts', Organic and Biomolecular Chemistry, vol. 13, pp. 6299 - 6312, http://dx.doi.org/10.1039/c5ob00779h

Tursky ML; Beck D; Thoms JAI; Huang Y; Kumari A; Unnikrishnan A; Knezevic K; Evans K; Richards LA; Lee E; Morris J; Goldberg L; Izraeli S; Wong JWH; Olivier J; Lock RB; MacKenzie KL; Pimanda JE, 2015, 'Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias', Leukemia, vol. 29, pp. 819 - 827, http://dx.doi.org/10.1038/leu.2014.299

Bruedigam C; Bagger FO; Heidel FH; Paine Kuhn C; Guignes S; Song A; Austin R; Vu T; Lee E; Riyat S; Moore AS; Lock RB; Bullinger L; Hill GR; Armstrong SA; Williams DA; Lane SW, 2014, 'Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy', Cell Stem Cell, vol. 15, pp. 775 - 790, http://dx.doi.org/10.1016/j.stem.2014.11.010

Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2014, 'Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 61, pp. 1493 - 1496, http://dx.doi.org/10.1002/pbc.25026

Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2014, 'Initial Testing (Stage 1) of the Notch Inhibitor PF-03084014, by the Pediatric Preclinical Testing Program (vol 61, pg 1493, 2014)', PEDIATRIC BLOOD & CANCER, vol. 61, pp. 1716 - 1716, http://dx.doi.org/10.1002/pbc.25186

Gorlick R; Kolb EA; Maris JM; Reynolds CP; Kang MH; Carol H; Lock RB; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA; Keir ST, 2014, 'Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 61, pp. 158 - 164, http://dx.doi.org/10.1002/pbc.24616

Jamieson WRAB, 2014, 'A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells', Biochemical Pharmacology, vol. 88, pp. 36 - 45, http://dx.doi.org/10.1016/j.bcp.2013.12.019

Kang MH; Reynolds CP; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2014, 'Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 61, pp. 1486 - 1489, http://dx.doi.org/10.1002/pbc.24989

Lock RB; Busfield S; Biondo M; Wong M; Ramshaw H; Lee E; Ghosh S; Braley H; Panousis C; Roberts A; He S; Thomas D; Fabri L; Vairo G; Lock REA, 2014, 'Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC', Leukemia, vol. advance online publication, 9 May 2014, pp. 2213 - 2221, http://dx.doi.org/10.1038/leu.2014.128

Lu H; Kojima K; Battula VL; Korchin B; Shi Y; Chen Y; Spong S; Thomas DA; Kantarjian H; Lock RB; Andreeff M; Konopleva M, 2014, 'Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: Anti-CTGF monoclonal antibody attenuates leukemia growth', Annals of Hematology, vol. 93, pp. 485 - 492, http://dx.doi.org/10.1007/s00277-013-1939-2

Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB, 2014, 'A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia', Blood Cancer Journal, vol. 4, http://dx.doi.org/10.1038/bcj.2014.52

Shahbazi J; Scarlett CJ; Norris MD; Liu B; Haber M; Tee AE; Carrier A; Biankin AV; London WB; Marshall GM; Lock RB; Liu T, 2014, 'Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', Oncotarget, vol. 5, pp. 4257 - 4268, http://dx.doi.org/10.18632/oncotarget.1991

Suryani S; Carol H; Chonghaile TN; Frismantas V; Sarmah C; High L; Bornhauser B; Cowley MJ; Szymanska B; Evans K; Boehm I; Tonna E; Jones L; Manesh DM; Kurmasheva RT; Billups C; Kaplan W; Letai A; Bourquin JP; Houghton PJ; Smith MA; Lock RB, 2014, 'Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts', Clin Cancer Res, vol. 20, pp. 4520 - 4531, http://dx.doi.org/10.1158/1078-0432.CCR-14-0259

Toscan CE; Failes T; Arndt GM; Lock RB, 2014, 'High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers', Journal of Biomolecular Screening, vol. 19, pp. 1391 - 1401, http://dx.doi.org/10.1177/1087057114546550

Wong NC; Bhadri VA; Maksimovic J; Parkinson-Bates M; Ng J; Craig JM; Saffery R; Lock RB, 2014, 'Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance', BMC Genomics, vol. 15, http://dx.doi.org/10.1186/1471-2164-15-416

Carol H; Gorlick R; Kolb EA; Morton CL; Moradi Manesh D; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak A; Hickson I; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock R, 2013, 'Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program', Pediatric Blood & Cancer, vol. 61, pp. 245 - 252, http://dx.doi.org/10.1002/pbc.24724

Kan C; Petti C; Bracken L; Maritz M; Xu N; O'Brien R; Yang C; Liu T; Yuan J; Lock RB; Mackenzie KL, 2013, 'Up-regulation of survivin during immortalization of human myofibroblasts is linked to repression of tumor suppressor p16(INK4a) protein and confers resistance to oxidative stress', The Journal of Biological Chemistry, vol. 288, pp. 12032 - 12041, http://dx.doi.org/10.1074/jbc.M112.447821

Lock RB, 2013, 'Initial Testing (Stage 1) of Temozolomide by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 60, pp. 783 - 790, http://dx.doi.org/10.1002/pbc.24368

Lock RB, 2013, 'Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 60, pp. 1325 - 1332, http://dx.doi.org/10.1002/pbc.24517

Lock RB, 2013, 'Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 60, pp. E42 - E45, http://dx.doi.org/10.1002/pbc.24451

Lock RB, 2013, 'Initial testing (stage 1) of the phosphatidylinositol 3’ kinase inhibitor, SAR245408 (XL147) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 60, pp. 791 - 798, http://dx.doi.org/10.1002/pbc.24301

Lock RB, 2013, 'Targeting acute myeloid leukemia by dual inhibition of P13K signalling and Cdk9-mediated Mcl-1 transcription', Blood, vol. 122, pp. 738 - 748, http://dx.doi.org/10.1182/blood-2012-08-447441

Lock RB, 2013, 'The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia', Clinical Cancer Research, vol. 19, pp. 1795 - 1805, http://dx.doi.org/10.1158/1078-0432.CCR-12-3613

Malyukova A; Papa R; O'Brien R; Giles JE; Trahair TN; Pozza LD; Sutton R; Liu T; Haber M; Norris MD; Lock RB; Marshall GM; Giles J, 2013, 'FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation', Leukemia, vol. 27, pp. 1053 - 1062, http://dx.doi.org/10.1038/leu.2012.361

Oram SH; Thoms J; Sive J; Calero-Nieto FJ; Kinston SJ; Schuette J; Knezevic K; Lock RB; Pimanda JE; Gottgens B, 2013, 'Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia', Leukemia, vol. 27, pp. 1348 - 1357, http://dx.doi.org/10.1038/leu.2013.2

Piazza RG; Magistroni V; Mogavero A; Andreoni F; Ambrogio C; Chiarle R; Mologni L; Bachmann PS; Lock RB; Collini P; Pelosi G; Gambacorti-Passerini C, 2013, 'Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex', Neoplasia, vol. 15, pp. 511 - 522, http://dx.doi.org/10.1593/neo.121784

Shahbazi J; Lock RB; Liu T, 2013, 'Tumor protein 53-induced nuclear protein 1 enhances p53 function and represses tumorigenesis', Frontiers in Genetics, vol. 13, pp. Art. No. 80, http://dx.doi.org/10.3389/fgene.2013.00080

Waibel M; Solomon VS; Knight DA; Ralli RA; Kim SK; Banks KM; Vidacs E; Virely C; Sia KCS; Bracken LS; Collins-Underwood R; Drenberg C; Ramsey LB; Meyer SC; Takiguchi M; Dickins RA; Levine R; Ghysdael J; Dawson MA; Lock RB; Mullighan CG; Johnstone RW, 2013, 'Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors', Cell Reports, vol. 5, pp. 1047 - 1059, http://dx.doi.org/10.1016/j.celrep.2013.10.038

2012, 'Correction: Disparate In Vivo Efficacy of FTY720 in Xenograft Models of Philadelphia Positive and Negative B-lineage Acute Lymphoblastic Leukemia', PloS one, vol. 7, http://dx.doi.org/10.1371/annotation/d7342840-682b-4ee2-bb41-7b41aa5dedf7

Batra V; Maris JM; Kang MH; Reynolds CP; Houghton PJ; Alexander D; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Billups CA; Smith MA, 2012, 'Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 59, pp. 749 - 752, http://dx.doi.org/10.1002/pbc.23364

Bhadri V; Trahair TN; Lock RB; bhadri , 2012, 'Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia', Journal of Paediatrics and Child Health, vol. 48, pp. 634 - 640, http://dx.doi.org/10.1111/j.1440-1754.2011.02212.x

Frolova O; Samudio I; Benito J; Jacamo R; Kornblau SM; Markovic A; Schober W; Lu H; Qiu YH; Buglio D; Mcqueen T; Pierce S; Shpall E; Konoplev S; Thomas D; Kantarjian H; Lock RB; Andreeff M; Konopleva M, 2012, 'Regulation of HIF-1 alpha signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment', Cancer Biology and Therapy, vol. 13, pp. 858 - 870, http://dx.doi.org/10.4161/cbt.20838

Gorlick R; Kolb EA; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock RB; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA, 2012, 'Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 59, pp. 1266 - 1274, http://dx.doi.org/10.1002/pbc.24073

Gorlick R; Maris JM; Houghton PJ; Lock RB; Carol H; Kurmasheva RT; Kolb EA; Reynolds CP; Kang MH; Billups CA; Smith MA, 2012, 'Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 59, pp. 518 - 524, http://dx.doi.org/10.1002/pbc.23412

Houghton PJ; Gorlick R; Kolb EA; Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Phelps D; Maris JM; Billups C; Smith MA, 2012, 'Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 58, pp. 191 - 199, http://dx.doi.org/10.1002/pbc.22935

Houghton PJ; Kang MH; Reynolds CP; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Maris JM; Billups CA; Smith MA, 2012, 'Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 58, pp. 636 - 639, http://dx.doi.org/10.1002/pbc.23167

Houghton PJ; Lock RB; Carol H; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Zhang MX; Madden SL; Teicher BA; Smith MA, 2012, 'Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 58, pp. 200 - 209, http://dx.doi.org/10.1002/pbc.23016

Kang MH; Reynolds CP; Houghton PJ; Alexander D; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Maris JM; Wozniak A; Smith MA, 2012, 'Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 59, pp. 185 - 188, http://dx.doi.org/10.1002/pbc.23154

Kolb EA; Gorlick R; Keir ST; Maris JM; Lock RB; Carol H; Kurmasheva RT; Reynolds CP; Kang MH; Wu J; Houghton PJ; Smith MA, 2012, 'Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling', Pediatric Blood and Cancer, vol. 58, pp. 815 - 818, http://dx.doi.org/10.1002/pbc.23290

Lock RB, 2012, 'Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia', PLoS ONE, vol. 7, pp. e36429, http://dx.doi.org/10.1371/journal.pone.0036429

Lock RB, 2012, 'Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 60, pp. 633 - 641, http://dx.doi.org/10.1002/pbc.24235

Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gorlick R; Kolb EA; Houghton PJ; Smith MA, 2012, 'Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 58, pp. 916 - 923, http://dx.doi.org/10.1002/pbc.23176

Markovic A; Mackenzie K; Lock RB, 2012, 'Induction of Vascular Endothelial growth factor secretion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling pathway', Molecular Cancer Therapeutics, vol. 11, pp. 183 - 193, http://dx.doi.org/10.1158/1535-7163.MCT-11-0503

Smith MA; Gorlick R; Kolb EA; Lock RB; Carol H; Maris JM; Keir ST; Morton CL; Reynolds CP; Kang MH; Arts J; Bashir T; Janicot M; Kurmasheva RT; Houghton PJ, 2012, 'Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 59, pp. 329 - 332, http://dx.doi.org/10.1002/pbc.23319

Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ, 2012, 'Erratum: Malcolm A. Smith, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Christopher L. Morton, Jianrong Wu, Peter G. Smith, Jie Yu and Peter J. Houghton. Initial testing of', Pediatric Blood & Cancer, vol. 59, pp. 772 - 772, http://dx.doi.org/10.1002/pbc.24291

Smith MA; Maris JM; Gorlick R; Kolb EA; Lock RB; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ, 2012, 'Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 59, pp. 246 - 253, http://dx.doi.org/10.1002/pbc.23357

Szymanska B; Wilczynska-Kalak U; Kang M; Liem N; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart C; Lock RB; Ingrid , 2012, 'Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts', PLoS One, vol. 7, pp. Article number e33894, http://dx.doi.org/10.1371/journal.pone.0033894

Barry JB; Lock RB, 2011, 'Small ubiquitin-related modifier-1: Wrestling with protein regulation', International Journal of Biochemistry and Cell Biology, vol. 43, pp. 37 - 40, http://dx.doi.org/10.1016/j.biocel.2010.09.022

Benito J; Shi Y; Szymanska B; Carol H; Boehm I; Lu H; Konoplev S; Fang W; Zweidler-McKay PA; Campana D; Borthakur G; Bueso-ramos C; Shpall E; Thomas DA; Jordan CT; Kantarjian H; Wilson WR; Lock RB; Andreeff M; Konopleva M; Ingrid , 2011, 'Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104', PLoS ONE, vol. 6, pp. e23108, http://dx.doi.org/10.1371/journal.pone.0023108

Bhadri V; Cowley MJ; Kaplan W; Trahair TN; Lock RB, 2011, 'Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia', BMC Genomics, vol. 12, pp. 1 - 13, http://dx.doi.org/10.1186/1471-2164-12-565

Carol H; Boehm I; Reynolds CP; Kang MH; Maris JM; Morton CL; Gorlick R; Kolb EA; Keir ST; Wu J; Wozniak AE; Yang Y; Manfredi M; Ecsedy J; Wang J; Neale G; Houghton PJ; Smith MA; Lock RB, 2011, 'Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer', Cancer Chemotherapy and Pharmacology, vol. 68, pp. 1291 - 1304, http://dx.doi.org/10.1007/s00280-011-1618-8

Davies C; Hogarth L; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB, 2011, 'p53-independent epigenetic repression of the p21WAF1 gene in T-cell acute lymphoblastic leukemia', The Journal of Biological Chemistry, vol. 286, pp. 37639 - 37650, http://dx.doi.org/10.1074/jbc.M111.272336

Houghton PJ; Lock RB; Carol H; Morton CL; Phelps D; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gu Y; Wilson WR; Smith MA, 2011, 'Initial Testing of the Hypoxia-Activated Prodrug PR-104 by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 57, pp. 443 - 453, http://dx.doi.org/10.1002/pbc.22921

Kolb AE; Gorlick R; Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Mans JM; Billups C; Smith MA; Houghton PJ, 2011, 'Initial Testing (Stage 1) of the IGF-1 Receptor Inhibitor BMS-754807 by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 56, pp. 595 - 603, http://dx.doi.org/10.1002/pbc.22741

Lu H; Battula VL; Shi Y; Lock RB; Spong S; Andreeff M; Konopleva M, 2011, 'Role of Connective Tissue Growth Factor (CTGF) in Survival and Chemosensitivity of Acute Lymphoblastic Leukemia', Blood, vol. 118, pp. 2593 - 2593, http://dx.doi.org/10.1182/blood.v118.21.2593.2593

Pimanda J; Thoms J; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Lock R; MacKenzie K; Gottgens B; Izraeli S, 2011, 'ERG PROMOTES T-ACUTE LYMPHOBLASTIC LEUKEMIA AND IS TRANSCRIPTIONALLY REGULATED IN LEUKEMIC CELLS BY A STEM CELL ENHANCER', EXPERIMENTAL HEMATOLOGY, vol. 39, pp. S108 - S108, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000293801700179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Reynolds CP; Kang MH; Keir ST; Gorlick R; Kolb EA; Lock RB; Maris JM; Carol H; Morton CL; Billups CA; Smith MA; Houghton PJ, 2011, 'Initial Testing of Lenalidomide by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 57, pp. 606 - 611, http://dx.doi.org/10.1002/pbc.22877

Smith MA; Maris JM; Lock RB; Kolb EA; Gorlick R; Keir ST; Carol H; Morton CL; Reynolds CP; Kang MH; Houghton PJ, 2011, 'Initial Testing (Stage 1) of the Polyamine Analog PG11047 by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 57, pp. 268 - 274, http://dx.doi.org/10.1002/pmic.201100005

Smith MPW; Wood SL; Zougman A; Ho JTC; Peng J; Jackson D; Cairns DA; Lewington AJP; Selby PJ; Banks RE, 2011, 'A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses.', Proteomics, vol. 11, pp. 2222 - 2235, http://dx.doi.org/10.1002/pmic.201100005

Thoms JAI; Birger Y; Foster S; Knezevic K; Kirshenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock RB; MacKenzie KL; Gottgens B; Izraeli S; Pimanda JE, 2011, 'ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer', Blood, vol. 117, pp. 7079 - 7089, http://dx.doi.org/10.1182/blood-2010-12-317990

Bachmann PS; Piazza RG; Janes M; Wong NC; Davies C; Mogavero A; Bhadri V; Szymanska B; Geninson G; Magistroni V; Cazaniga G; Biondi A; Miranda-saavedra D; Gottgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-passerini C; Pimanda JE; Lock RB, 2010, 'Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition', Blood, vol. 116, pp. 3013 - 3022, http://dx.doi.org/10.1182/blood-2010-05-284968

Benito J; Shi Y; Szymanska B; Carol H; Bohem I; Lu H; Konoplev S; Fang W; Kornblau SM; Zweidler-McKay P; Wilson W; Campana D; Borthakur G; Bueso-Ramos CE; Kantarjian HM; Shpall EJ; Thomas DA; Jordan CT; Lock RB; Andreeff M; Konopleva M, 2010, 'Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104', Blood, vol. 116, pp. 868 - 868, http://dx.doi.org/10.1182/blood.v116.21.868.868

Bhadri VA; Cowley MJ; Kaplan W; Lock RB, 2010, 'The NOD/SCID Xenograft Model Provides Clinically-Relevant Insights Into Glucocorticoid-Induced Gene Expression In Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)', Blood, vol. 116, pp. 2493 - 2493, http://dx.doi.org/10.1182/blood.v116.21.2493.2493

Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Watkins A; Smith MA; Lock RB, 2010, 'Initial Testing of Topotecan by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 54, pp. 707 - 715, http://dx.doi.org/10.1002/pbc.22352

Carol H; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ; Lock RB, 2010, 'Initial Testing (Stage 1) of the Akt Inhibitor GSK690693 by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 55, pp. 1329 - 1337, http://dx.doi.org/10.1002/pbc.22710

High L; Szymanska B; Wilczynska-kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB; High L, 2010, 'The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs', Molecular Pharmacology, vol. 77, pp. 483 - 494, http://dx.doi.org/10.1124/mol.109.060780

Houghton PJ; Morton CL; Gorlick R; Lock RB; Carol H; Reynolds CP; Kang MH; Maris JM; Keir ST; Kolb EA; Wu J; Wozniak AW; Billups CA; Rubinstein L; Smith MA, 2010, 'Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program', Molecular Cancer Therapeutics, vol. 9, pp. 101 - 112, http://dx.doi.org/10.1158/1535-7163.MCT-09-0952

Keir ST; Maris JM; Lock RB; Kolb EA; Gorlick R; Carol H; Morton CL; Reynolds CP; Kang MH; Watkins A; Houghton PJ; Smith MA, 2010, 'Initial Testing (Stage 1) of the Multi-Targeted Kinase Inhibitor Sorafenib by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 55, pp. 1126 - 1133, http://dx.doi.org/10.1002/pbc.22712

Kolb EA; Gorlick R; Houghton PJ; Morton CL; Keir ST; Carol H; Lock RB; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA, 2010, 'Initial Testing (Stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 55, pp. 668 - 677, http://dx.doi.org/10.1002/pbc.22576

Lu H; Battula VL; Korchin B; Spong S; Canizales M; Lock RB; Andreeff M; Konopleva M, 2010, 'Targeting Connective Tissue Growth Factor (CTGF) In Acute Lymphoblastic Leukemia Pre-Clinical Models: Anti-CTGF Monoclonal Antibody Attenuates Tumor Growth In Mouse Models of ALL', Blood, vol. 116, pp. 3257 - 3257, http://dx.doi.org/10.1182/blood.v116.21.3257.3257

Maris JM; Morton CL; Gorlick R; Kolb EA; Lock RB; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ, 2010, 'Initial Testing of the Aurora Kinase A Inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)', Pediatric Blood and Cancer, vol. 55, pp. 26 - 34, http://dx.doi.org/10.1002/pbc.22430

Napier CE; Veas LA; Kan C; Taylor LM; Yuan J; Wen VW; James A; O'Brien TA; Lock RB; Mackenzie K, 2010, 'Mild hyperoxia limits hTR levels, telomerase activity, and telomere length maintenance in hTERT-transduced bone marrow endothelial cells', Biochimica et Biophysica ACTA - Molecular Cell Research, vol. 1803, pp. 1142 - 1153, http://dx.doi.org/10.1016/j.bbamcr.2010.06.010

Oram SH; Thoms JAI; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Gottgens B, 2010, 'A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients', Oncogene, vol. 29, pp. 5796 - 5808, http://dx.doi.org/10.1038/onc.2010.320

Samuels AL; Peeva VK; Papa R; Firth MJ; Francis RW; Beesley AH; Lock RB; Kees UR, 2010, 'Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia', BMC Genomics, vol. 11, http://dx.doi.org/10.1186/1471-2164-11-256

Smith MA; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Kang MH; Reynolds CP; Maris JM; Watkins AE; Houghton PJ, 2010, 'Initial Testing (Stage 1) of Mapatumumab (HGS-ETR1) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 54, pp. 307 - 310, http://dx.doi.org/10.1002/pbc.22188

Carol H; Lock RB; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA, 2009, 'Initial Testing (Stage 1) of the Kinesin Spindle Protein Inhibitor Ispinesib by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 53, pp. 1255 - 1263, http://dx.doi.org/10.1002/pbc.22056

Gorlick R; Kolb EA; Houghton PJ; Morton CL; Phelps D; Schaiquevich P; Stewart C; Keir ST; Lock RB; Reynolds CP; Maris JM; Wu J; Smith MA, 2009, 'Initial Testing (Stage 1) of Lapatinib by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 53, pp. 594 - 598, http://dx.doi.org/10.1002/pbc.21989

Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge M; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick J; Lock RB, 2009, 'Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor alpha Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells', Cell Stem Cell, vol. 5, pp. 31 - 42, http://dx.doi.org/10.1016/j.stem.2009.04.018

Kang MH; Harutyunyan N; Hall CP; Papa R; Lock RB, 2009, 'Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma', British Journal of Haematology, vol. 145, pp. 389 - 393, http://dx.doi.org/10.1111/j.1365-2141.2009.07631.x

Keshelava N; Houghton PJ; Morton CL; Lock RB; Carol H; Keir ST; Maris JM; Reynolds CP; Gorlick R; Kolb EA; Wu J; Smith MA, 2009, 'Initial Testing (Stage 1) of Vorinostat (SAHA) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 53, pp. 505 - 508, http://dx.doi.org/10.1002/pbc.21988

Lee EM; Lock RB, 2009, 'Targeting of AML-leukemic stem cells with monoclonal antibodies', Future Oncology, vol. 5, pp. 1327 - 1330, http://dx.doi.org/10.2217/FON.09.115

Lock RB; Bachmann PS; Piazza RG; Davies C; James M; Wong NC; Bhadri VA; Mogavero A; Magistroni V; Gambacorti-Passerini C; Saffery R; Craig JM; Pimanda JE; Marshall GM, 2009, 'Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition.', Blood, vol. 114, pp. 939 - 939, http://dx.doi.org/10.1182/blood.v114.22.939.939

Morton CL; Houghton PJ; Gorlick R; Kolb EA; Lock RB; Carol H; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA, 2009, 'Initial Testing of Aplidin by the Pediatric Pre-Clinical Testing Program', Pediatric Blood and Cancer, vol. 53, pp. 509 - 512, http://dx.doi.org/10.1002/pbc.21976

Yuan J; Yang BMP; Zhong Z; Shats I; Milyavsky M; Rotter V; Lock RB; Reddel R; Mackenzie K, 2009, 'Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase', Oncogene, vol. 28, pp. 2678 - 2689, http://dx.doi.org/10.1038/onc.2009.136

Brands K; Colvin EK; Williams LJ; Wang R; Lock RB; Tuch BE, 2008, 'Reduced immunogenicity of first-trimester human fetal pancreas.', Diabetes, vol. 57, pp. 627 - 634, http://dx.doi.org/10.2337/db07-0720a

Choo A; Palladinetti P; Holmes TA; Basu S; Shen S; Lock RB; O Brien T; Symonds GP; Dolnikov A, 2008, 'siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth.', International Journal of Oncology, vol. 33, pp. 175 - 183

Dilda P; Perrone G; Philp A; Lock RB; Dawes IW; Hogg PJ, 2008, 'Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid', International Journal of Biochemistry and Cell Biology, vol. 40, pp. 1016 - 1029, http://dx.doi.org/10.1016/j.biocel.2007.11.002

Henderson M; Choi S; Beesley A; Baker DL; Wright DC; Papa R; Murch A; Campbell L; Lock RB; Norris MD; Haber M; Kees UR, 2008, 'A xenograft model of infant leukaemia reveals a complex MLL translocation', British Journal of Haematology, vol. 140, pp. 716 - 719, http://dx.doi.org/10.1111/j.1365-2141.2007.06966.x

Houghton P; Morton C; Kolb EA; Gorlick R; Lock RB; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA, 2008, 'Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.', Pediatric Blood and Cancer, vol. 50, pp. 799 - 805, http://dx.doi.org/10.1002/pbc.21296

Houghton P; Morton C; Kolb EA; Lock RB; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA, 2008, 'Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 50, pp. 37 - 45, http://dx.doi.org/10.1002/pbc.21214

Kolb A; Gorlick R; Houghton P; Morton C; Lock RB; Tajbakhsh M; Maris JM; Reynolds CP; Keir ST; Billups CA; Smith MA, 2008, 'Initial testing of dasatinib by the Pediatric Preclinical Testing Program.', Pediatric Blood and Cancer, vol. 50, pp. 1198 - 1206, http://dx.doi.org/10.1002/pbc.21368

Kolb EA; Gorlick R; Houghton P; Morton C; Lock RB; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA, 2008, 'Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program.', Pediatric Blood and Cancer, vol. 50, pp. 1190 - 1197, http://dx.doi.org/10.1002/pbc.21450

Lock RB; Carol H; Houghton P; Morton CR; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Wu JJ; Smith MS, 2008, 'Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 50, pp. 1181 - 1189, http://dx.doi.org/10.1002/pbc.21433

Lock RB; Neale G; Su X; Morton CL; Phelps D; Gorlick R; Reynolds CP; Maris JM; Friedman HSEA, 2008, 'Molecular characterization of the pediatric preclinical testing panel', Clin Cancer Res, vol. 14, pp. 4572 - 4583, http://dx.doi.org/10.1158/1078-0432.CCR-07-5090

Maris JM; Courtright J; Houghton P; Morton C; Gorlick R; Kolb EA; Lock RB; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA, 2008, 'Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.', Pediatric Blood and Cancer, vol. 50, pp. 581 - 587, http://dx.doi.org/10.1002/pbc.21232

Maris JM; Courtright J; Houghton P; Morton C; Kolb EA; Lock RB; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA, 2008, 'Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.', Pediatric Blood and Cancer, vol. 51, pp. 42 - 48, http://dx.doi.org/10.1002/pbc.21535

Ong V; Liem N; Schmid M; Verrills NM; Papa R; Marshall GM; Mackenzie K; Kavallaris M; Lock RB, 2008, 'A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts', Journal of Pharmacology and Experimental Therapeutics, vol. 324, pp. 434 - 442, http://dx.doi.org/10.1124/jpet.107.128926

Smith MA; Morton CL; Phelps DA; Kolb EA; Lock RB; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ, 2008, 'Stage 1 Testing and Pharmacodynamic Evaluation of the HSP90 Inhibitor Alvespimycin (17-DMAG, KOS-1022) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 51, pp. 34 - 41, http://dx.doi.org/10.1002/pbc.21508

Tajbakhsh M; Houghton P; Morton CL; Kolb A; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB, 2008, 'Initial testing of Cisplatin by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, vol. 50, pp. 992 - 1000, http://dx.doi.org/10.1002/pbc.21263

Tuch B; Wu W; Brands K; Colvin E; Sung J; Williams L; Lock R; Wang R, 2008, 'EARLY HUMAN FETAL PANCREAS AS A THERAPY FOR DIABETES', Transplantation, vol. 86, pp. 561 - 561, http://dx.doi.org/10.1097/01.tp.0000331028.21911.80

Bachmann PS; Gorman R; Papa R; Marshall GM; Lock RB, 2007, 'Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia', Cancer research, vol. 67, pp. 4482 - 4490, http://dx.doi.org/10.1158/0008-5472.CAN-06-4244

Bachmann PS; Lock RB, 2007, 'In vivo models of childhood leukemia for preclinical drug testing', Current Drug Targets, vol. 8, pp. 773 - 783, http://dx.doi.org/10.2174/138945007780830809

Houghton P; Morton C; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb A; Zhang W; Lock RB; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA, 2007, 'The Paediatric Preclinical Testin Program: Description of models and early testing results.', Pediatric Blood and Cancer, vol. 49, pp. 928 - 940

Houghton PJ; Maris JM; Courtright J; Friedman H; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Keshelava N; Reynolds P; Morton CL; Smith MA, 2007, 'Initial testing of the histone deacetylase inhibitor Vorinostat by the Pediatric Preclinical Testing Program', MOLECULAR CANCER THERAPEUTICS, vol. 6, pp. 3600S - 3601S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000251969000805&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Houghton PJ; Maris JM; Courtright J; Friedman HS; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Keshelava N; Reynolds CP; Morton CL; Smith MA, 2007, 'Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib', MOLECULAR CANCER THERAPEUTICS, vol. 6, pp. 3471S - 3471S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000251969000417&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Houghton PJ; Maris JM; Friedman HS; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Keshlava N; Reynolds CP; Morton CL; Smith MA, 2007, 'Pediatric preclinical testing program (PPTP) evaluation of the fully human anti-IGF-1R antibody SCH 717454', MOLECULAR CANCER THERAPEUTICS, vol. 6, pp. 3405S - 3405S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000251969000221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kang MH; Kang Y; Szymanska B; Wilczynska-Kalak U; Sheard M; Harned TM; Lock RB; Reynolds CP, 2007, 'Activity of vincristine, L-ASP and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo', Blood, vol. 110, pp. 2057 - 2066, http://dx.doi.org/10.1182/blood-2007-03-080325

Lee E; Bachmann PS; Lock RB, 2007, 'Xenograft models for the preclinical evaluation of new therapies in acute leukemia', Leukemia and Lymphoma, vol. 48, pp. 659 - 668, http://dx.doi.org/10.1080/10428190601113584

Markovic A; Mackenzie KL; Lock RB, 2007, 'Induction of vascular endothelial growth factor secretion in acute leukemia cells via the FLT-3 signaling pathway', MOLECULAR CANCER THERAPEUTICS, vol. 6, pp. 3344S - 3344S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000251969000042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Morton CL; Papa RA; Lock RB; Houghton PJ, 2007, 'Preclinical chemotherapeutic tumor models of common childhood cancers: solid tumors, acute lymphoblastic leukemia and disseminated neuroblastoma', Curent Protocols in Pharmacology, vol. Chapter 14, pp. 14.8.1 - 18.4.20

Smith MA; Maris JM; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Keshelava N; Reynolds CP; Morton C; Houghton PJ, 2007, 'Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG', Journal of Clinical Oncology, vol. 25, pp. 3575 - 3575, http://dx.doi.org/10.1200/jco.2007.25.18_suppl.3575

Whiteford CC; Bilke S; Greer B; Chen Q; Braunschweig TA; Cenacchi N; Wei JS; Smith MA; Houghton PJ; Morton CL; Reynolds CP; Lock RB; Gorlick R; Khanna C; Thiele CJ; Takikita M; Catchpoole DR; Hewitt SM; Khan J, 2007, 'Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis', Cancer research, vol. 67, pp. 32 - 40, http://dx.doi.org/10.1158/0008-5472.CAN-06-0610

Xue C; Haber M; Flemming C; Marshall GM; Lock RB; Mackenzie K; Norris MD; Gurova K; Gudkov A, 2007, 'p53 determines multidrug sensitivity of childhood neuroblastoma.', Cancer research, vol. 67, pp. 10351 - 10360, http://dx.doi.org/10.1158/0008-5472.CAN-06-4345

Choo A; Palladinetti P; Passioura T; Shen S; Lock R; Symonds G; Dolnikov A, 2006, 'The role of IRF1 and IRF2 transcription factors in leukaemogenesis', Current Gene Therapy, vol. 6, pp. 543 - 550

Choo A; Palladinetti P; Passioura TJ; Shen S; Symonds GP; Dolnikov A, 2006, 'The role of IRF1 and IRF2 transcription factors in leukaemogenesis', Current Gene Therapy, vol. 6, pp. 543 - 550, http://dx.doi.org/10.2174/156652306778520683

Houghton PJ; Maris JM; Friedman HS; Keir ST; Lock RB; Gorlick R; Kolb EA; Reynolds CP; Morton C; Smith MA, 2006, 'Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor ispinesib (SB-715992)', EJC SUPPLEMENTS, vol. 4, pp. 98 - 98, http://dx.doi.org/10.1016/S1359-6349(06)70318-4

Houghton PJ; Morton CL; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb EA; Zhang W; Lock RB; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA, 2006, 'The Pediatric Preclinical Testing Program: description of models and early testing results', Pediatric Blood and Cancer, vol. 49, pp. 928 - 940, http://dx.doi.org/10.1002/pbc.21078

Hsu AK; Kerr BA; Jones KL; Lock RB; Hart DN; Rice AM, 2006, 'RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy', Biology of Blood and Marrow Transplantation, vol. 12, pp. 855 - 867, http://dx.doi.org/10.1016/j.bbmt.2006.05.004

Mackenzie K; Lock RB, 2006, 'An endothelial metronome breast cancer?', Blood, vol. 108, pp. 407 - 408, http://dx.doi.org/10.1182/blood-2006-05-019695

Shaw SE; Haylock DN; Johnston HM; Lock R; Nilsson SK, 2006, 'The Role of Hyaluronic Acid in Normal and Perturbed Hemopoietic Stem Cell Biology.', Blood, vol. 108, pp. 708 - 708, http://dx.doi.org/10.1182/blood.v108.11.708.708

Smith MA; Maris JM; Keir ST; Friedman HS; Lock RB; Kolb EA; Keshelava N; Reynolds CP; Morton C; Houghton PJ, 2006, 'Pediatric preclinical testing program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825)', EJC SUPPLEMENTS, vol. 4, pp. 101 - 101, http://dx.doi.org/10.1016/S1359-6349(06)70327-5

Smith MA; Maris JM; Keir ST; Lock RB; Gorlick R; Kolb EA; Keshelava N; Reynolds CP; Morton C; Houghton PJ, 2006, 'Pediatric preclinical testing program (PPTP) evaluation of the VEGFR-2 inhibitor AZD2171', EJC SUPPLEMENTS, vol. 4, pp. 34 - 35, http://dx.doi.org/10.1016/S1359-6349(06)70108-2

Verrills NM; Liaw TY; Lock RB; Kavallaris M; Liem N; Hood B, 2006, 'Proteomic anlaysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, vol. 6, pp. 1681 - 1694, http://dx.doi.org/10.1002/pmic.200500417

Wen VW; Wu K; Baksh S; Hinselwood RA; Lock RB; Clark SJ; Moore MA; Mackenzie K, 2006, 'Telomere-driven karyotypic complexity concurs with p16INK4a inactivation in TP53 competent immortal endothelial cells', Cancer research, vol. 66, pp. 10691 - 10700, http://dx.doi.org/10.1158/0008-5472.CAN-06-0979

Xu B; Wang BJ; Li AM; Lock R, 2006, 'Effect of glucocorticoid on the expression of Puma in acute lymphoblastic leukemia', Chinese Journal of Contemporary Pediatrics, vol. 8, pp. 151 - 154

Bachmann PS; Gorman R; MacKenzie KL; Lutze-Mann L; Lock RB, 2005, 'Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor', Blood, vol. 105, pp. 2519 - 2526, http://dx.doi.org/10.1182/blood-2004-05-2023

Markovic A; Mackenzie K; Lock RB, 2005, 'FLT-3: a new focus in the understanding of acute leukemia', International Journal of Biochemistry and Cell Biology, vol. 37, pp. 1168 - 1172, http://dx.doi.org/10.1016/j.biocel.2004.12.005

Bendall LJ; Nilsson SK; Khan NI; Bonnet C; Lock RB; papa R; Bradstock KF; Gottlieb DJ, 2004, 'Role of CD44 variant exon 6 in acute lymphoblastic leukemia: Association with altered bone marrow localisation and inceased tumor burden.', Leukemia, vol. 18, pp. 1308 - 1319, http://dx.doi.org/10.1038/sj.leu.2403393

Liem N; Papa R; Milross CG; Schmid M; Tajbakhsh M; Choi S; Ramirez C; Rice AM; Haber M; Norris MD; Lock RB, 2004, 'Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies', Blood, vol. 103, pp. 3905 - 3914, http://dx.doi.org/10.1182/blood-2003-08-2911

Taylor LM; James A; Schuller C; Brce J; Lock RB; Mackenzie K, 2004, 'Inactivation of p16INK4a, with retention of pRB and p53/p21cip1 function, in human M3C5 fibroblasts that overcome a telomere-independent crisis during immortalization', The Journal of Biological Chemistry, vol. 279, pp. 43634 - 43635, http://dx.doi.org/10.1074/jbc.M402388200

Lock RB, 2003, 'TCL1: A new drug target in lymphoid and ger-cell malignancies', International Journal of Biochemistry and Cell Biology, vol. 35, pp. 1614 - 1618, http://dx.doi.org/10.1016/S1357-2725(03)00146-8

Houghton PJ; Adamson PC; Blaney S; Fine HA; Gorlick R; Haber M; Helman L; Hirschfeld S; Hollingshead MG; Israel MA; Lock RB; Maris JM; Merlino G; Patterson W; Reynolds CP; Shannon K; Yu A; Yu J; Smith MA, 2002, 'Testing of new agents in childhood cancer preclinical models(meeting summary)', Clinical Cancer Research, vol. 8, pp. 3646 - 3657

Lock RB; Liem N; Farnsworth ML; Milross CG; Xue C; Tajbakhsh M; Haber M; Norris MD; Marshall GM; Rice AM, 2002, 'The non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of Childhood acute lymphblastic leukemia reveals intrinsic differences in biological characteristics at diagnosis and relapse', Blood, vol. 99, pp. 4100 - 4108, http://dx.doi.org/10.1182/blood.V99.11.4100

Catchpoole DR; Lock RB, 2001, 'The Potential Tumour Suppressor role for caspase-9 in the childhood malignancy, neoroblastoma', European Journal of Cancer, vol. 37, pp. 2217 - 2221, http://dx.doi.org/10.1016/S0959-8049(01)00273-8

Catts VS; Haber M; Norris MD; Lutze-Mann L; Lock RB, 2001, 'High Level resistance to Glucocorticoids, assosiated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance', Leukemia, vol. 15, pp. 929 - 935, http://dx.doi.org/10.1038/sj.leu.2402128

Marshall GM; Norris MD; Lock RB; Peaston AE; Gardaneh M; Franco VA; Hocker JE; Murphy K; Farnsworth ML; Catchpoole DR; Haber M, 2001, 'MRP1 gene expression level regulates the death and differentation response of neuroblastoma cells', British Journal of Cancer, vol. 85, pp. 1564 - 1571, http://dx.doi.org/10.1054/bjoc.2001.2144

Murphy KD; Ranganathan V; Farnsworth ML; Kavallaris M; Lock RB, 2000, 'Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumour cells', Cell death and differentiation, vol. 7, pp. 102 - 111, http://dx.doi.org/10.1038/sj.cdd.4400597

Murphy KD; Streips UN; Lock RB, 2000, 'Bcl-2 inhibits a Fas-induced conformational change in the Bas N terminus and Bax mitchondrial translocation', The Journal of Biological Chemistry, vol. 275, pp. 17225 - 17228, http://dx.doi.org/10.1074/jbc.C900590199

Elliott MJ; Murphy KD; Stribinskiene L; Ranganathan V; Sturges E; Farnsworth ML; Lock RB, 1999, 'Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide', Cancer Chemotherapy and Pharmacology, vol. 44, pp. 1 - 11, http://dx.doi.org/10.1007/s002800050938

Murphy KD; Streips UN; Lock RB, 1999, 'Bax membrane insertion during Fas (CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2', Oncogene, vol. 18, pp. 5991 - 5999, http://dx.doi.org/10.1038/sj.onc.1203001

Turnbull RM; Meczes EL; Rogers M; Lock RB; Sullivan DR; Finlay GJ; Baguley BC; Austin CA, 1999, 'Carbanate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases II and B', Cancer Chemotherapy and Pharmacology, vol. 44, pp. 275 - 282, http://dx.doi.org/10.1007/s002800050978

Turnbull RM; Meczes EL; Rogers MP; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA, 1999, 'Carbamate analogues of amsacrine active against non-cycling cells: Relative activity against topoisomerases IIα and β', Cancer Chemotherapy and Pharmacology, vol. 44, pp. 275 - 282, http://dx.doi.org/10.1007/s002800050978

Elliot M; Stribinskiene L; Lock RB, 1998, 'Expression of Bcl-2 in human epithelial tumor (HeLA) cells enhances clonogenic survival following exposure to 5-fluoro-2-deoxyuridine or staurosporine, but not following exposure to etoposide or dosorubicin', Cancer Chemotherapy and Pharmacology, vol. 41, pp. 457 - 463, http://dx.doi.org/10.1007/s002800050767

LaRocca RV; Lock RB, 1998, 'Surveying the frontiers of cancer research and therapy', Louisville Medicine, vol. 45, pp. 511 - 513

Lock RB; Thompson BS; Sullivan DM; Stribinskiene L, 1997, 'Potentiation of etoposide-induced apoptosis by staurosporine in human tumor cells is associated with events downstream of DNA-protein complex formation', Cancer Chemother Pharmacol, vol. 39, pp. 399 - 409, http://dx.doi.org/10.1007/s002800050590

Lock RB; Stribinskiene L, 1996, 'Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival', Cancer Research, vol. 56, pp. 4006 - 4012

Lock RB; Thompson BS; Stribinskiene L, 1996, 'Differential ability of 2,4-dinitrophenol to modulate etoposide cytotoxicity in mammalian tumor cell lines associated with inhibition of macromolecular synthesis', Int J Oncology, vol. 8, pp. 305 - 311

Sullivan DM; Feldhoff PW; Lock RB, 1995, 'Characterization of an altered DNA topoisomerase IIα from a mitoxantrone resistant mammalian cell line which is hypersensitive to DNA crosslinking agents', Int J Oncology, vol. 7, pp. 1383 - 1393

Eastman A; Grant S; Lock R; Tritton T; Van Houten N; Yuan J, 1994, 'Cell Death in Cancer and Development', Cancer Research, vol. 54, pp. 2812 - 2818

Lock RB; Galperina OV; Feldhoff RC; Rhodes LJ, 1994, 'Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells', Cancer Research, vol. 54, pp. 4933 - 4939

Lock RB; Keeling PK, 1993, 'Responses of HeLa and Chinese hamster ovary p34cdc2/cyclin-B kinase in relation to cell cycle perturbations induced by etoposide', Int J Oncology, vol. 3, pp. 33 - 42

Lock RB, 1992, 'Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide', Cancer Research, vol. 52, pp. 1817 - 1822

Webb CD; Latham MD; Lock RB; Sullivan MD, 1991, 'Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line', Cancer Research, vol. 51, pp. 6543 - 6549

Lock RB; Ross WE, 1990, 'Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells', Cancer Research, vol. 50, pp. 3761 - 3766

Lock RB; Ross WE, 1990, 'Possible role for p34cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells', Cancer Research, vol. 50, pp. 3767 - 3771

Shen J-W; Subjeck JR; Lock RB; Ross WE, 1989, 'Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response', Mol Cell Biol, vol. 9, pp. 3284 - 3291, http://dx.doi.org/10.1128/MCB.9.8.3284

Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RPEA, 1988, 'Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I', Cancer Research, vol. 48, pp. 6404 - 6410

Hill BT; Whelan RDH; Bellamy AS; Lock RB, 1988, 'The differential expression of drug resistance or collateral sensitivity in a continuous human tumor cell line established from a squamous cell carcinoma of the tongue following in vitro exposure to fractionated X-irradiation', The differential expression of drug resistance or collateral sensitivity in a continuous human tumor cell line established from a squamous cell carcinoma of the tongue following in vitro exposure to f, pp. 167 - 173

Hill BT; Whelan RDH; Hosking LK; Shellard SA; Bedford P; Lock RB, 1988, 'Interactions between antitumor drugs and radiation in mammalian tumor cell lines: Differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposure in vitro', NCI Monographs, pp. 177 - 181

Hill BT; Whelan RDH; Hosking LK; Shellard SA; Bedford P; Lock RB, 1988, 'Interactions between antitumor drugs and radiation in mammalian tumor cell lines: differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposure in vitro', NCI Monographs, vol. 6, pp. 171 - 181

Lock RB; Hill BT, 1988, 'Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines', Int J Cancer, vol. 42, pp. 373 - 381, http://dx.doi.org/10.1002/ijc.2910420312

Bellamy AS; Whelan RDH; Lock RB; Hill BT, 1987, 'Effects of fractionated X-irradiation on subsequent response to acute X-irradiation in two human tumour cell lines in vitro', Int J Radiat Biol, vol. 51, pp. 681 - 691, http://dx.doi.org/10.1080/09553008414552211

Lock RB; Ross WE, 1987, 'DNA topoisomerases in cancer therapy', Anti-Cancer Drug Design, vol. 2, pp. 151 - 164

LOCK RB; HILL BT, 1986, 'DRUG-RESISTANCE INVITRO - INTERACTIONS BETWEEN X-IRRADIATION, ETOPOSIDE AND VINCRISTINE', BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 14, pp. 618 - 619, http://dx.doi.org/10.1042/bst0140618

Germon Z; Sillar J; Mannan A; Duchatel R; Staudt D; Murray H; Findlay I; Jackson E; McEwen H; Douglas A; McLachlan T; Schjenken J; Skerrett-Bryne D; Huang H; Melo-Braga M; Plank M; Alvaro F; Chamberlain J; Iuliis GD; Aitken J; Nixon B; Wei A; Enjeti A; Lock R; Larsen M; Lee H; de Bock C; Verrills N; Dun M, 2022, Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies, http://dx.doi.org/10.1101/2022.03.09.483687

Connerty P; Moles E; deBock C; Jayatilleke N; Smith JL; Meshinchi S; Mayoh C; Kavallaris M; Lock RB, 2021, 'Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for paediatric acute myeloid leukaemia', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, presented at Abstracts: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; October 7-10, 2021, http://dx.doi.org/10.1158/1535-7163.TARG-21-P143

Lock RB; Evans K; El-Zein N; Earley EJ; Erickson SW; Teicher BA; Smith MA, 2021, 'Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 3039 - 3039, presented at Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA, http://dx.doi.org/10.1158/1538-7445.am2021-3039

Lock RB; Evans K; El-Zein N; Earley EJ; Erickson SW; Teicher BA; Smith MA, 2021, 'Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263506374&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lock RB; Evans K; El-Zein N; Earley EJ; Erickson SW; Teicher BA; Sung V; Smith MA, 2021, 'Abstract LB171: The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL)', in Cancer Research, American Association for Cancer Research (AACR), pp. LB171 - LB171, presented at Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA, http://dx.doi.org/10.1158/1538-7445.am2021-lb171

Lock RB; Evans K; El-Zein N; Earley EJ; Erickson SW; Teicher BA; Sung V; Smith MA, 2021, 'The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL).', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263501401&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lock RB; Evans K; El-Zein N; Lannutti BJ; Jessen KA; Earley EJ; Erickson SW; Smith MA; Kurmasheva R; Houghton PJ, 2021, 'Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)', in Cancer Research, American Association for Cancer Research (AACR), pp. 3038 - 3038, presented at Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA, http://dx.doi.org/10.1158/1538-7445.am2021-3038

Lock RB; Evans K; El-Zein N; Lannutti BJ; Jessen KA; Earley EJ; Erickson SW; Smith MA; Kurmasheva R; Houghton PJ, 2021, 'Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC).', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263506373&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Atkinson C; Tactacan C; Kamili A; Saletta F; Gana C; Eden G; Mayoh C; Lock R; Norris M; Haber M; Gifford A; Trahair T; Fletcher J, 2020, 'Abstract A35: P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. A35 - A35, presented at Abstracts: AACR Special Conference on the Advances in Pediatric Cancer Research; September 17-20, 2019; Montreal, QC, Canada, http://dx.doi.org/10.1158/1538-7445.pedca19-a35

Barahona P; Fletcher J; Fuentes-Bolanos N; Gauthier M-E; Haber M; Lock RB; Marshall GM; Mayoh C; Mould E; Nagabushan S; Norris M; O’Brien T; Sherstyuk A; Thomas D; Trahair T; Tucker K; Warby M; Wong M; Ziegler DS; Tyrrell VJ; Ekert P; Cowley MJ; Lau L; Quang D-AK, 2020, 'Abstract A52: Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with high-risk cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. A52 - A52, presented at Abstracts: AACR Special Conference on the Advances in Pediatric Cancer Research; September 17-20, 2019; Montreal, QC, Canada, http://dx.doi.org/10.1158/1538-7445.pedca19-a52

Dong-Anh K-Q; Nagabushan S; Manoharan N; Arndt G; Barahona P; Cowley MJ; Ekert PG; Failes T; Bolanos NF; Gauthier M; Gifford AJ; Haber M; Kumar A; Lock RB; Marshall GM; Mayoh C; Mould E; Norris MD; Gopalakrishnan A; Omer N; Trebilcock P; Trahair TN; Tsoli M; Tucker K; Wong M; Tyrrell V; Lau L; Ziegler DS, 2020, 'PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 22, pp. 302 - 302, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606080100118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Haber M; Cowley MJ; Ekert P; Lau L; Mould E; Gifford A; Lock RB; Marshall GM; Norris MD; O'Brien T; Dong AKQ; Thomas D; Trahair T; Tucker K; Ziegler DS; Tyrrell V, 2020, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer in Australia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-SY09-02

Houghton PJ; Kurmasheva RT; Erickson S; Smith MA; Lock RB; Evans K; Toscan C, 2020, 'Prospective validation of single mouse testing (SMT) by the pediatric preclinical testing consortium (PPTC)', Vol. 138, pp. S18, http://dx.doi.org/10.1016/S0959-8049(20)31111-4

Khuong-Quang D-A; Nagabushan S; Manoharan N; Arndt G; Barahona P; Cowley MJ; Ekert PG; Failes T; Bolanos NF; Gauthier M; Gifford AJ; Haber M; Kumar A; Lock RB; Marshall GM; Mayoh C; Mould E; Norris MD; Gopalakrishnan A; Omer N; Trebilcock P; Trahair TN; Tsoli M; Tucker K; Wong M; Tyrrell V; Lau L; S, Ziegler D, 2020, 'DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM', in Neuro-oncology, Vol. 22, pp. iii302 - iii302

Lock RB; Evans K; Jones CD; Erickson SW; Teicher BA; Unger TJ; Landesman Y; Smith MA, 2020, 'The XPO1 inhibitior, eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-4181

Mohamed SMA; Sia K; Friedrich K-H; Wohlmann A; Savvides S; Schofield P; Christ D; Kavallaris M; Lock RB; Bayat N, 2020, 'A Novel Engineered Single-Chain Antibody Fragment for Targeting Pediatric Philadelphia Chromosome-like Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, ELECTR NETWORK, Vol. 136, presented at 62nd Annual Meeting of the American-Society-of-Hematology (ASH), ELECTR NETWORK, 05 December 2020 - 08 December 2020, http://dx.doi.org/10.1182/blood-2020-138421

Atkinson C; Tactacan C; Kamili A; Saletta F; Gana C; Eden G; Mayoh C; Lock R; Norris M; Haber M; Gifford A; Trahair T; Fletcher J, 2019, 'P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 61 - 61, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Atkinson C; Tactacan CM; Kamili A; Saletta F; Gana C; Eden GL; Mayoh C; Lock RB; Norris MD; Haber M; Gifford AJ; Trahair TN; Fletcher JI, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 4741 - 4741, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.am2019-4741

Atkinson C; Tactacan CM; Kamili A; Saletta F; Gana C; Eden GL; Mayoh C; Lock RB; Norris MD; Haber M; Gifford AJ; Trahair TN; Fletcher JI, 2019, 'Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-4741

Barahona P; Fletcher J; Fuentes-Bolanos N; Gauthier M-E; Haber M; Lock RB; Marshall GM; Mayoh C; Mould E; Nagabushan S; Norris M; O'Brien T; Sherstyuk A; Thomas D; Trahair T; Tucker K; Warby M; Wong M; Ziegler DS; Tyrrell VJ; Ekert P; Cowley MJ; Lau L; Quang D-AK, 2019, 'Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with highrisk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 70 - 71, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Earley E; Gorlick R; Houghton PJ; Mans JM; Li X-N; Lock RB; Teicher B; Smith MA; Erickson SW, 2019, 'Re-evaluating sample sizes in preclinical testing of patient-derived xenografts', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-LB-321

Earley E; Gorlick R; Houghton PJ; Maris JM; Li X-N; Lock RB; Teicher B; Smith MA; Erickson SW, 2019, 'Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-lb-321

Evans K; El-Zein N; Jones C; Erickson SW; Guo Y; Teicher BA; Adams S; Zweidler-McKay PA; Smith MA; Lock RB, 2019, 'Abstract 4820: Pediatric preclinical testing consortium evaluation of the CD123 antibody drug conjugate, IMGN632, against xenograft models of pediatric acute lymphoblastic leukemia', in Experimental and Molecular Therapeutics, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-4820

Evans K; El-Zein N; Jones C; Erickson SW; Guo Y; Teicher BA; Adams S; Zweidler-McKay PA; Smith MA; Lock RB, 2019, 'Pediatric preclinical testing consortium evaluation of the CD123 antibody drug conjugate, IMGN632, against xenograft models of pediatric acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-4820

Haber M; Gamble L; Xiao L; Pandher R; Somers K; Murray J; Khan A; Yu D; Franshaw L; Burns MR; Tsoli M; Ehteda A; Cesare A; O'Connor A; Mussai F; de Santo C; Cheng P; Korotchkina L; Gurova K; Tyrrell V; Mould E; Lau L; Dong AKQ; Mayoh C; Arndt G; Barahona P; Failes T; Fletcher J; Fuentes-Bolanos N; Gauthier M-E; Gifford A; Grebert-Wade D; Kamili A; Kumar A; Nagabushan S; O'Brien T; Strong P; Sherstyuk A; Thomas D; Trahair T; Tucker K; Warby M; Wong M; Xie J; Evans K; Lock R; Chernova OB; Henderson M; Gudkov AV; Ekert P; Cowley MJ; Marshall GM; Ziegler DS; Norris MD, 2019, 'Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 23 - 24, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Li J; Troche C; Zhang JH; Shrimp J; Roth JS; Jing D; Swaroop A; Kulis M; Oyer J; Will C; Dupere-Richer D; Riva A; Pipe C; Sobn A; Norton S; Bennett RL; Shen M; Hall MD; Lock RB; Licht JD, 2019, 'A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-126910

Lock RB; Evans K; Jones CD; El-Zein N; Bendak K; Toscan CE; Mayoh C; Erickson SW; Teicher BA; Smith MA, 2019, 'Pediatric Preclinical Testing Consortium Evaluation of the Novel Anti-Microtubule Drug E7130 in Xenograft Models of Early T-Cell Precursor Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-123867

Lock RB; Evans K; Jones CD; El-Zein N; Erickson SW; Beaussant-Cohen S; Kelley EL; Teicher BA; Smith MA, 2019, 'The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-19-C004

Lock RB; Toscan CE; Jing D; Mayoh C, 2019, 'Reversal of glucocorticoid resistance in pediatric acute lymphoblastic leukemia is dependent on restoring BIM expression', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-19-A123

Mould EV; Lau L; Arndt G; Barahona P; Cowley MJ; Ekert P; Failes T; Fletcher J; Gifford A; Grebert-Wade D; Haber M; Kamili A; Kumar A; Lock RB; Marshall GM; Mayoh C; Norris M; O'Brien T; Quang DAK; Strong P; Sherstyuk A; Trahair T; Tsoli M; Tucker K; Warby M; Wong M; Xie J; Ziegler DS; Tyrrell V, 2019, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3111

Quang DAK; Lau L; Cowley MJ; Ekert PG; Gifford AJ; Haber M; Lock R; Marshall G; Mayoh C; Mould E; Norris M; O'Brien T; Trahair T; Tyrrell V; Ziegler DS, 2019, 'Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children and Adolescents with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S504 - S505, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458005162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Rokita JL; Rathi K; Cardenas M; Upton K; Jayaseelan J; Cross K; Pfeil J; Ritenour L; Modi A; Farrel A; Way G; Kendsersky N; Patel K; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm J; Marshall G; Tyrrell V; Kalletla K; Braun F; Qi L; Du Y; Zhang H; Lindsay H; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan A; Leraas K; Coppens S; Doddapaneni H; Momin Z; Zhang W; Sacks G; Hart L; Krytska K; Mosse Y; Gatto G; Sanchez Y; Greene C; Diskin S; Vaske OM; Haussler D; Gastier-Foster J; Kolb A; Gorlick R; Li X-N; Reynolds P; Kurmasheva R; Houghton P; Smith M; Lock R; Raman P; Wheeler D; Maris J, 2019, Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design, http://dx.doi.org/10.1101/566455

Teicher BA; Lock RB; Evans K; Houghton PJ; Kurmasheva RT; Gorlicki R; Erickson S; Wishka D; Morris J; Difilippantonio M; Collins JE; Smith MA; Doroshow JH, 2019, 'Abstract 3839: Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts', in Cancer Research, American Association for Cancer Research (AACR), pp. 3839 - 3839, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.am2019-3839

Teicher BA; Lock RB; Evans K; Houghton PJ; Kurmasheva RT; Gorlicki R; Erickson S; Wishka D; Morris J; Difilippantonio M; Collins JE; Smith MA; Doroshow JH, 2019, 'Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-3839

Tsoli M; Lau L; Barahona P; Mayoh C; Failes T; Wong M; Sherstyuk A; Gifford AJ; Kumar A; Mould E; Ung C; Tolhurst O; Gopalakrishnan A; Grebert-Wade D; Strong P; Trebilcock P; Lock R; Tyrrell V; Trahair T; Tucker K; Warby M; Arndt G; Norris M; Haber M; Marshall G; O'Brien T; Dong AKQ; Cowley M; Ekert P; Ziegler DS, 2019, 'RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRA-TM PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CA, San Francisco, Vol. 21, pp. 118 - 118, presented at 5th Biennial Conference of the Society-for-Neuro-Oncology on Pediatric Neuro-Oncology Basic and Translational Research, CA, San Francisco, 03 May 2019 - 04 May 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473243700229&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Jing D; Huang Y; Liu X; Sia K; Poulos RC; Span M; Zhang C; Mi J; Wong JWH; Beck D; Pimanda JE; Lock RB, 2018, 'Lymphocyte-specific chromatin accessibility predetermines glucocorticoid resistance in acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-3173

Karsa M; Failes T; Arndt GM; Kees UR; Haber M; Norris MD; Sutton R; Lock RB; Somers K; Henderson MJ, 2018, 'PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia', Vol. 3, pp. A181 - A181, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.431

Krytska K; Evans K; Pritchard T; Tsang M; Yung R; Mosse YP; Erickson SW; Guo Y; Baloglu E; Landesman Y; Jensen KA; Senapedis W; Teicher BA; Smith MA; Lock RB; Maris JM, 2018, 'Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-17-LB-B14

Lock RB; Evans K; Pritchard T; Erickson SW; Guo Y; Claremon DA; McGeehan GM; Teicher BA; Smith MA, 2018, 'Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-3187

Lock RB; Evans K; Pritchard T; Toscan C; Mayoh C; Teicher B; Kurmasheva RT; Houghton PJ; Smith M, 2018, 'A Single Mouse Trial Platform for Evaluation of Novel Agents in Acute Lymphoblastic Leukemia By the Pediatric Preclinical Testing Consortium', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, presented at 60th Annual Meeting of the American-Society-of-Hematology (ASH), CA, San Diego, 01 December 2018 - 04 December 2018, http://dx.doi.org/10.1182/blood-2018-99-113207

Lock RB; Evans K; Yung R; Pritchard T; Teicher BA; Duan J; Guo Y; Erickson SW; Smith MA, 2018, 'The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-17-LB-B16

Mould E; Lau L; Arndt G; Barahona P; Cowley M; Ekert P; Failes T; Fletcher J; Gifford A; Haber M; Kamili A; Kumar A; Lock R; Marshall G; Mayoh C; Mead S; Norris M; O'Brien T; Pinese M; Dong AKQ; Trahair T; Tsoli M; Tucker K; Warby M; Wong M; Xie J; Ziegler D; Tyrrell V, 2018, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-138

Teicher BA; Lock RB; Collins JM; Gorlick R; Kolb EA; Houghton PJ; Kurmasheva RT; Li X-N; Erickson SW; Guo Y; Evans K; Qi L; Smith MA, 2018, 'Pediatric Preclinical Testing Consortium evaluation of 4 '-thio-2 '-deoxycytidine (TdCyd) and 5-aza-4 '-thio-2 '-deoxycytidine (Aza-TdCyd)', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-17-LB-B12

Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin J; Gayevski V; Kumar A; Kaplan W; Ekert P; Franshaw L; Gifford A; Weber M; Rodriguez M; Mayoh C; Cohn R; Arndt G; Lock R; Tyrrell V; Norris M; Haber M; Lau L; Dong AKQ; Wong M; Trahair T; Marshall GM; Cowley MJ; Ziegler DS, 2018, 'Integrated genomics: drug screening and personalized xenograft development approach to identify precision treatments for aggressive pediatric brain tumors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-137

Evans K; Pritchard T; Henderson MJ; Somers K; Karsa M; Cheung L; Yung R; Erickson SW; Korotchkina L; Chernova O; Gudkov A; Smith MA; Lock RB, 2017, 'The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibits in vitro and in vivo efficacy against patient-derived xenograft models of high-risk acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-1942

Karsa M; Somers K; Mariana A; Failes T; Arndt GM; Kees UR; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ, 2017, 'REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, SPAIN, Madrid, Vol. 102, pp. 27 - 27, presented at 22nd Congress of the European-Hematology-Association, SPAIN, Madrid, 22 June 2017 - 25 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404127001055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lau L; Byrne J; Ekert PG; Failes T; Fellowes A; Fletcher J; Gifford A; Haber M; Kumar A; Lock R; Marshall G; McCowage GB; Mould E; Norris M; Trahair T; Tsoli M; Tyrrell V; Wadham C; Xie J; Ziegler DS, 2017, 'Pilot study of a comprehensive precision medicine platform for children with high-risk cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 06 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.10539

Somers K; Middlemiss S; Biktasova A; Karsa M; Cheung L; Kosciolek A; Evans K; Mayoh C; Kees UR; Korotchkina L; Chernova OB; Lock RB; Gudkov AV; Haber M; Norris MD; Henderson MJ, 2017, 'Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-1175

Wakefield C; Quinn V; Doolan E; Fardell J; Tucker K; Patenaude A; Marshall K; Lock R; Signorelli C; Georgiou G; Cohn R, 2017, 'The use of Murine Models of Chemosensitivity to Anticancer Agents in Childhood Cancer Clinical Care: Survivor, Parent and Community Acceptability and Willingness-to-Pay', in PEDIATRIC BLOOD & CANCER, WILEY, pp. S60 - S61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000408978201113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sutton R; Law T; Venn NC; Wadham C; Mould EVA; Norris MD; Kotecha RS; Marschalek R; Meyer C; Dalla-Pozza L; Marshall GM; Lock RB; Trahair TN, 2016, 'Comparison of MRD Levels and Gene Expression Patterns in MLL-R Versus Non-MLL Infant ALL', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 128, presented at 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), CA, San Diego, 03 December 2016 - 06 December 2016, http://dx.doi.org/10.1182/blood.V128.22.1740.1740

Alruwetei AM; Carol H; Sutton R; Marshall GM; Lock RB, 2015, 'Evaluation of Patient-Derived Xenografts for Modeling Outcome of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, Vol. 126, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368021800016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Churchman ML; Jones L; Evans K; Richmond J; Shapiro IM; Pachter JA; Weaver DT; Houghton PJ; Smith MA; Lock RB; Mullighan CG, 2015, 'Efficacy of Focal Adhesion Kinase Inhibition in Combination with Dasatinib in BCR-ABL1 Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, Vol. 126, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, http://dx.doi.org/10.1182/blood.V126.23.3766.3766

Haber M; Murray J; Gamble L; Carnegie-Clark A; Webber H; Ruhle M; Henderson MJ; Middlemass S; Carter D; Tsoli M; Ehteda A; Simon S; Oberthuer A; Fischer M; Gurova K; Burkhart C; Purmal A; Lock RB; Ziegler D; Marshall GM; Gudkov AV; Norris MD, 2015, 'The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1611

Jones L; Richmond J; Evans K; Lock RB, 2015, 'Bioluminescence imaging enhances analysis of drug response in a patient-derived xenograft model of pediatric acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1631

Li KL; Bray SC; Iarossi D; Adams J; Zhong L; Noll B; Rahaman MH; Richmond J; To LB; Lewis ID; Lock RB; Wang S; D'Andrea RJ, 2015, 'Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, http://dx.doi.org/10.1182/blood.V126.23.1365.1365

Lock R; Houghton P; Smith M, 2015, 'A REVIEW OF NEW AGENTS TESTED BY THE PEDIATRIC PRECLINICAL TESTING PROGRAM AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS', in PEDIATRIC BLOOD & CANCER, WILEY-BLACKWELL, Vol. 62, pp. S211 - S211, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361247200258&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Richmond J; Evans K; Robbins A; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB, 2015, 'In vivo and in vitro efficacy of birinapant in preclinical models of Ph-like pediatric acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1620

Smith MA; Kang M; Reynolds PC; Lock RB; Carol H; Gorlick R; Kolb AE; Maris JM; Keir ST; Billups CA; Kurmasheva R; Houghton PJ, 2015, 'Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP)', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1615

Smith MA; Lock R; Carol H; Maris JM; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ, 2015, 'Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1616

Suryani S; Evans K; Richmond J; Robbins A; Bracken L; Kurmasheva R; Houghton PJ; Smith MA; Lock RB, 2015, 'Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-3276

Bruedigam C; Bagger FO; Heidel FH; Kuhn C; Guignes S; Song A; Austin R; Vu T; Lee EM; Moore AS; Lock RB; Bullinger L; Hill GR; Lane SW, 2014, 'Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)', in BLOOD, AMER SOC HEMATOLOGY, Vol. 124, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349242706008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dolai S; Sia KCS; Robbins AK; Zhong L; Heatley S; Vincent T; Hochgraefe F; Kurmasheva RT; White DL; Houghton PJ; Smith MA; Teachey DT; Daly RJ; Raftery MJ; Lock RB, 2014, 'Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling', in BLOOD, AMER SOC HEMATOLOGY, Vol. 124, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349242705041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dolnikov A; Klamer G; Chitranjan A; Xu N; Shen S; Micklethwaite KP; Lock RB; O'Brien T, 2014, 'Identifying the Factors Modulating the Efficacy of CAR-T Cell Therapy', in BLOOD, AMER SOC HEMATOLOGY, Vol. 124, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349242706217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dolnikov A; Klamer G; Shen S; Chitranjan A; Carol H; Lock R; O'Brien T, 2014, 'IDENTIFYING THE FACTORS MODULATING THE EFFICACY OF CAR-T CELL THERAPY', in CYTOTHERAPY, ELSEVIER SCI LTD, Vol. 16, pp. S7 - S7, http://dx.doi.org/10.1016/j.jcyt.2014.01.015

Dolnikov A; Rossi S; Xu N; Klamer G; Shen S; Micklethwaite KP; Lock RB; O'Brien T, 2014, '5-Aza-2 '-Deoxycytidine Promotes Cytotoxic Effect of CART-Cells on Leukaemia Cells', in BLOOD, AMER SOC HEMATOLOGY, CA, San Francisco, presented at 56th Annual Meeting of the American-Society-of-Hematology, CA, San Francisco, 06 December 2014 - 09 December 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349233806021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Houghton P; Lock R; Carol H; Gorlick R; Kolb A; Maris J; Keir S; Wu J; Kang M; Reynolds P; Kurmasheva R; Smith M, 2014, 'The Pediatric Preclinical Testing Program (PPTP): Analysis of the first 10 years in vivo testing', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 131 - 132, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SPAIN, European Org Res & Treatment Canc, Barcelona, 18 November 2014 - 21 November 2014, http://dx.doi.org/10.1016/S0959-8049(14)70538-6

Maude SL; Dolai S; Delagdo-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT, 2014, 'Targeting the Jak/Stat signaling pathway is highly effective in xenograft models of early T cell precursor (ETP) acute lymphoblastic leukemia (ALL)', Vol. 74, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-997

Maude SL; Dolai S; Delgado-Martin C; Hunger SP; Loh ML; Mullighan CG; Hermiston ML; Grupp SA; Lock R; Teachey DT, 2014, 'EARLY T-CELL PRECURSOR (ETP) ACUTE LYMPHOBLASTIC LEUKEMIA IS CHARACTERIZED BY ABERRANT ACTIVATION OF THE JAK/STAT PATHWAY AND PROFOUND RESPONSES TO RUXOLITINIB IN XENOGRAFT MODELS', in PEDIATRIC BLOOD & CANCER, WILEY-BLACKWELL, pp. S109 - S109, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343932100014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Shahbazi J; Scarlett CJ; Norris M; Liu B; Haber M; Tee AE; Carrier A; Biankin AV; London WB; Marshall GM; Lock R; Liu T, 2014, 'Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', Vol. 74, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-5138

Smith M; Kang M; Reynolds P; Gorlick R; Kolb A; Maris J; Lock R; Carol H; Keir S; Billups C; Kurmasheva R; Houghton P, 2014, 'Pediatric preclinical testing program (PPTP) evaluation of BMN 673, an inhibitor of poly-adp ribose polymerase (PARP), with temozolomide (TMZ)', Vol. 74, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-3969

Smith M; Kang M; Reynolds P; Lock R; Carol H; Gorlick R; Kolb A; Maris J; Keir S; Wu J; Kurmasheva R; Houghton P, 2014, 'Pediatric Preclinical Testing Program (PPTP) Evaluation of the p53-MDM2 Antagonist MK-8242', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 131 - 131, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SPAIN, European Org Res & Treatment Canc, Barcelona, 18 November 2014 - 21 November 2014, http://dx.doi.org/10.1016/S0959-8049(14)70536-2

Houghton P; Kang M; Reynolds P; Gorlick R; Kolb A; Maris J; Keir S; Carol H; Lock R; Billups C; Kurmasheva R; Landesman Y; Shacham S; Kauffman M; Smith MA, 2013, 'Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the XPO1/CRM1 inhibitor KPT-330', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-LB-354

Houghton P; Kang MH; Reynolds P; Lock R; Carol H; Gorlick R; Kolb A; Maris J; Keir S; Billups C; Kurmasheva R; Smith M, 2013, 'Abstract 2758: Pediatric preclinical testing program (PPTP) stage 1 evaluation of MLN0128, a potent TOR kinase inhibitor.', in Cancer Research, American Association for Cancer Research (AACR), pp. 2758 - 2758, presented at Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am2013-2758

Houghton PJ; Kang M; Reynolds CP; Lock RB; Carol H; Gorlick R; Kolb EA; Maris JM; Keir ST; Billups CA; Kurmasheva RT; Smith MA, 2013, 'Abstract 2754: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the antimicrotubule agents cabazitaxel and docetaxel.', in Cancer Research, American Association for Cancer Research (AACR), pp. 2754 - 2754, presented at Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am2013-2754

Lock RB; Richmond J; High L; Carol H; Evans K; Mendomo AM; Kurmasheva RT; Houghton PJ; Smith MA, 2013, 'Effective Targeting Of The P53/MDM2 As In Preclinical Models Of Infant MLL-Rearranged Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, presented at 55th Annual Meeting of the American-Society-of-Hematology, LA, New Orleans, 07 December 2013 - 10 December 2013, http://dx.doi.org/10.1182/blood.V122.21.71.71

Manesh DM; Carol H; Evans K; Richmond J; Jamieson S; Wilson WR; Houghton PJ; Smith MA; Lock RB, 2013, 'AKR1C3 is a potential biomarker of T-cell acute lymphoblastic leukemia sensitivity to the pre-prodrug PR-104.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-2745

Shahbazi J; Lock R; Liu T, 2013, 'BET bromodomain inhibition as a therapeutic strategy to target N-Myc in neuroblastoma', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S356 - S356, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843602301&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smith M; Kang M; Reynolds P; Gorlick R; Kolb A; Maris J; Lock R; Carol H; Keir S; Billups C; Kurmasheva R; Houghton P, 2013, 'Pediatric Preclinical Testing Program (PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ).', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, Vol. 12, http://dx.doi.org/10.1158/1535-7163.TARG-13-C206

Suryani S; Carol H; Frimantas V; Bornhauser B; Sarmah C; Chonghaile T; Evans K; Tonna E; Jones L; Letai A; Bourquin J-P; Houghton PJ; Smith MA; Lock RB, 2013, 'Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, presented at AACR Special Conference on Pediatric Cancer at the Crossroads - Translating Discovery into Improved Outcomes, CA, San Diego, 03 November 2013 - 06 November 2013, http://dx.doi.org/10.1158/1538-7445.PEDCAN-B26

Thomas D; Powell JA; Parker MW; Ekert PG; Lock RB; Huang DC; Nilsson SK; Recher C; Wei AH; Guthridge MA, 2013, 'The selective targeting of cell survival pathways in leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.FBCR13-A19

Toscan C; Failes T; Arndt G; Lock R, 2013, 'High throughput screen to identify compounds that reverse glucocorticoid resistance in pediatric leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-4550

Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Martin K; Ghosh S; Braley H; Tomasetig V; Panousis C; Vairo G; Roberts AW; He SZ; Sprigg N; Thomas D; DeWitte M; Lock RB; Lopez AF; Nash A, 2012, 'CSL362: A Monoclonal Antibody to Human Interleukin-3 Receptor (CD123), Optimized for NK Cell-Mediated Cytotoxicity of AML Stem Cells', in BLOOD, AMER SOC HEMATOLOGY, GA, Atlanta, presented at 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), GA, Atlanta, 08 December 2012 - 11 December 2012, http://dx.doi.org/10.1182/blood.V120.21.3598.3598

Carol H; Lock R; Maris J; Keir S; Gorlick R; Kolb A; Kang M; Reynolds P; Wu J; Kurmasheva R; Houghton P; Smith M, 2012, 'Pediatric Preclinical Testing Program (PPTP) evaluation of the JAK inhibitor AZD1480', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, presented at Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL, http://dx.doi.org/10.1158/1538-7445.AM2012-LB-318

Lee EM; Yee D; Busfield SJ; Vairo G; Lock RB, 2012, 'A Neutralizing Antibody (CSL362) Against the Interleukin-3 Receptor alpha-Chain Augments the Efficacy of a Cytarabine/Daunorubicin Induction-Type Therapy in Preclinical Xenograft Models of Acute Myelogenous Leukemia', in BLOOD, AMER SOC HEMATOLOGY, GA, Atlanta, presented at 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), GA, Atlanta, 08 December 2012 - 11 December 2012, http://dx.doi.org/10.1182/blood.V120.21.3599.3599

Smith M; Kang M; Lock R; Carol H; Gorlick R; Kolb A; Maris J; Keir S; Kurmasheva R; Houghton P, 2012, 'Pediatric Preclinical Testing Program (PPTP) Stage 1 Evaluation of Eribulin', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, pp. 105 - 105, presented at 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, 06 November 2012 - 09 November 2012, http://dx.doi.org/10.1016/S0959-8049(12)72143-3

Smith M; Keir S; Maris J; Kolb A; Reynolds P; Kang M; Carol H; Lock R; Gorlick R; Kurmasheva R; Billups C; Houghton P, 2012, 'Pediatric Preclinical Testing Program (PPTP) evaluation of volasertib (BI 6727), a Polo-like kinase (PLK) inhibitor', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, presented at Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL, http://dx.doi.org/10.1158/1538-7445.AM2012-LB-317

Smith MA; Carol H; Evans K; Richmond J; Kang M; Reynolds CP; Chunduru S; Graham MA; Geier B; Kurmasheva R; Houghton PJ; Lock RB, 2012, 'Birinapant (TL32711), a Small Molecule Smac Mimetic, Induces Regressions in Childhood Acute Lymphoblastic Leukemia (ALL) Xenografts That Express TNF alpha and Synergizes with TNF alpha in Vitro - A Report From the Pediatric Preclinical Testing Program (PPTP)', in BLOOD, AMER SOC HEMATOLOGY, GA, Atlanta, presented at 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), GA, Atlanta, 08 December 2012 - 11 December 2012, http://dx.doi.org/10.1182/blood.V120.21.3565.3565

Suryani S; Sia KCS; Bracken L; Carol H; Evans K; Kurmasheva R; Houghton PJ; Smith MA; Lock RB, 2012, 'Dual Inhibition of JAK/STAT and MAPK Pathways Results in Synergistic Cell Killing of JAK-Mutated Pediatric Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, GA, Atlanta, presented at 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), GA, Atlanta, 08 December 2012 - 11 December 2012, http://dx.doi.org/10.1182/blood.V120.21.3562.3562

Carol H; Lock RB; Maris JM; Keir ST; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Morton CL; Smith PG; Thomas M; McDonald A; Houghton PJ; Smith MA, 2011, 'Pediatric Preclinical Testing Program (PPTP) evaluation of the NEDD8-activating enzyme (NAE) inhibitor MLN4924', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, presented at Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL, http://dx.doi.org/10.1158/1538-7445.AM2011-740

High LM; Papa RA; Armstrong SA; Lock RB, 2011, 'In vivo exposure of infant leukemia to the BH3-mimetic ABT-263 selects for a cell death-resistant phenotype', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-LB-23

Houghton PJ; Lock RB; Carol H; Morton CL; Gorlick R; Kolb EA; Kier ST; Reynolds CP; Kang MH; Maris JM; Billups CA; Smiths MA, 2011, 'Pediatric preclinical testing program (PPTP) evaluation of the non-camptothecin topoisomerase 1 targeted agent Genz644282', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-5358

Houghton PJ; Maris JM; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Kurmasheva RT; Whiteman KR; Smith MA, 2011, 'Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. C105 - C105, presented at Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA, http://dx.doi.org/10.1158/1535-7163.targ-11-c105

Keir ST; Morton CL; Kolb EA; Gorlick R; Caroi H; Lock R; Kang MH; Reynolds CP; Maris JM; Wu J; Smith MA; Houghton PJ, 2011, 'Pediatric preclinical testing program (PPTP) evaluation of the DNA methylating agent temozolomide', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, presented at Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL, http://dx.doi.org/10.1158/1538-7445.AM2011-5356

Lock RB; Carol H; Szymanska B; Boehm I; Evans K; Houghton PJ; Smith MA, 2011, 'Abstract C107: The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia.', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. C107 - C107, presented at Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA, http://dx.doi.org/10.1158/1535-7163.targ-11-c107

Lu H; Battula VL; Shi Y; Lock RB; Spong S; Andreeff M; Konopleva M, 2011, 'Role of Connective Tissue Growth Factor (CTGF) in Survival and Chemosensitivity of Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, pp. 1113 - 1113, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000299597103459&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Reynolds CP; Kang MH; Carol H; Lock RB; Gorlick R; Kolb EA; Alexander D; Kurmasheva RT; Keir ST; Maris JM; Wu J; Houghton PJ; Smith MA, 2011, 'Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. C106 - C106, presented at Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA, http://dx.doi.org/10.1158/1535-7163.targ-11-c106

Smith MA; Kang MH; Reynolds CP; Lock RB; Carol H; Gorlick R; Kolb EA; Maris JM; Keir ST; Billups CA; Kurmasheva RT; Houghton PJ, 2011, 'Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. C103 - C103, presented at Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA, http://dx.doi.org/10.1158/1535-7163.targ-11-c103

Benito J; Shi Y; Szymanska B; Carol H; Bohem I; Lu H; Konoplev S; Fang W; Kornblau SM; Zweidler-McKay P; Wilson W; Campana D; Borthakur G; Bueso-Ramos CE; Kantarjian HM; Shpall EJ; Thomas DA; Jordan CT; Lock RB; Andreeff M; Konopleva M, 2010, 'Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, pp. 379 - 380, presented at 52nd Annual Meeting of the American-Society-of-Hematology (ASH), FL, Orlando, 04 December 2010 - 07 December 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000289662200869&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bhadri VA; Cowley MJ; Kaplan W; Lock RB, 2010, 'The NOD/SCID Xenograft Model Provides Clinically-Relevant Insights Into Glucocorticoid-Induced Gene Expression In Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (ALL).', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, pp. 1033 - 1034, presented at 52nd Annual Meeting of the American-Society-of-Hematology (ASH), FL, Orlando, 04 December 2010 - 07 December 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000289662202716&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Houghton PJ; Maris JM; Courtright J; Friedman HS; Kier ST; Lock RB; Carol H; Gorlick R; Kolb EA; Kang M; Reynolds CP; Morton CL; Smith MA, 2010, 'Abstract 5265: Pediatric preclinical testing program (PPTP) stage 1 evaluation of BMS-754807 IGF-1 receptor inhibitor', in Cancer Research, American Association for Cancer Research (AACR), pp. 5265 - 5265, presented at Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am10-5265

Lock R, 2010, 'XENOGRAFT MODELS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA', in EXPERIMENTAL HEMATOLOGY, ELSEVIER SCIENCE INC, AUSTRALIA, Melbourne, pp. S111 - S112, presented at 39th Annual Scientific Meeting of the ISEH - Society-for-Hematology-and-Stem-Cells, AUSTRALIA, Melbourne, 15 September 2010 - 18 September 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000281168900228&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lu H; Battula VL; Korchin B; Spong S; Canizales M; Lock RB; Andreeff M; Konopleva M, 2010, 'Targeting Connective Tissue Growth Factor (CTGF) In Acute Lymphoblastic Leukemia Pre-Clinical Models: Anti-CTGF Monoclonal Antibody Attenuates Tumor Growth In Mouse Models of ALL', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, pp. 1335 - 1336, presented at 52nd Annual Meeting of the American-Society-of-Hematology (ASH), FL, Orlando, 04 December 2010 - 07 December 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000289662203588&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smith MA; Maris JM; Courtright J; Friedman HS; Kier ST; Lock RB; Carol H; Gorlick R; Kolb EA; Kang M; Reynolds CP; Morton CL; Houghton PJ, 2010, 'Abstract 5266: Pediatric Preclinical Testing Program (PPTP) evaluation of the CDK inhibitor SCH 727965', in Cancer Research, American Association for Cancer Research (AACR), pp. 5266 - 5266, presented at Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am10-5266

Smith MA; Maris JM; Keir ST; Lock RB; Carol H; Kolb EA; Kang MH; Reynolds CP; Hickson I; Houghton PJ, 2010, 'Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of JNJ-26481585, a second generation histone deacetylase inhibitor', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, GERMANY, Berlin, pp. 49 - 49, presented at 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, GERMANY, Berlin, 16 November 2010 - 19 November 2010, http://dx.doi.org/10.1016/S1359-6349(10)71840-1

Thomas D; Powell JA; Barry EF; Woodcock J; Ekert PG; Green BD; Lee EM; Lock RB; Nilsson SK; Haylock DN; Lopez AF; Guthridge MA, 2010, 'THE PROTEIN KINASE ACTIVITY OF PHOSPHOINOSITIDE 3-KINASE ALPHA PROMOTES AUTONOMOUS CELL SURVIVAL IN AML STEM/PROGENITOR CELLS', in EXPERIMENTAL HEMATOLOGY, ELSEVIER SCIENCE INC, AUSTRALIA, Melbourne, pp. S87 - S87, presented at 39th Annual Scientific Meeting of the ISEH - Society-for-Hematology-and-Stem-Cells, AUSTRALIA, Melbourne, 15 September 2010 - 18 September 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000281168900175&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carol H; Lock R; Houghton P; Morton C; Maris J; Courtright J; Kolb E; Gorlick R; Friedman H; Keir S; Kang M; Reynolds C; Smith M, 2009, 'Pediatric preclinical testing program (PPTP) evaluation of the Akt inhibitor GSK690693', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702803487&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dilda P; Decollogne S; Weerakoon L; Allen J; Lock R; Hogg P, 2009, 'Eliminating the pro-drug properties of the tumor angiogenesis inhibitor, 4-(N-(S-glutathionylacetyl)amino)phenylarsinous acid (GSAO), results in markedly enhanced anti-tumor activity', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702604245&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Houghton PJ; Maris JM; Courtright J; Friedman HS; Keir ST; Lock RB; Carol H; Kolb EA; Gorlick R; Kang M; Reynolds CP; Morton CL; Smith MA, 2009, 'Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. C57 - C57, presented at Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA, http://dx.doi.org/10.1158/1535-7163.targ-09-c57

Kolb E; Gorlick R; Houghton P; Morton C; Maris J; Courtright J; Carol H; Lock R; Friedman H; Keir S; Kang M; Reynolds C; Smith M, 2009, 'Pediatric Preclinical Testing Program (PPTP) evaluation of the multi-targeted kinase inhibitor Sorafenib', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702803490&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lock RB; Bachmann PS; Piazza RG; Davies C; James M; Wong NC; Bhadri VA; Mogavero A; Magistroni V; Gambacorti-Passerini C; Saffery R; Craig JM; Pimanda JE; Marshall GM, 2009, 'Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, pp. 387 - 388, presented at 51st Annual Meeting of the American-Society-of-Hematology, LA, New Orleans, 05 December 2009 - 08 December 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000272725801119&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Maris J; Courtright J; Houghton P; Morton C; Kolb E; Gorlick R; Carol H; Lock R; Friedman H; Keir S; Kang M; Reynolds C; Smith M, 2009, 'Pediatric Preclinical Testing Program (PPTP) evaluation of the novel polyamine analogue PG11047', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702803488&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mayer L; Carol H; Morton CL; Harasym T; Smith MA; Lock RB, 2009, 'Evaluation of CPX-351 (cytarabine:daunorubicin) liposome injection efficacy in acute lymphoblastic leukemia (ALL) xenograft models', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, presented at Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA, http://dx.doi.org/10.1158/1535-7163.TARG-09-A135

Morton C; Houghton P; Maris J; Courtright J; Kolb E; Gorlick R; Carol H; Lock R; Friedman H; Keir S; Kang M; Reynolds C; Smith M, 2009, 'Pediatric Preclinical Testing Program (PPTP) evaluation of PR-104', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702803489&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Nowak D; Akagi T; Papa R; Kawamata N; Thoennissen N; Okamoto R; Hofmann W; Kato M; Ogawa S; Lock R; Koeffler P, 2009, 'High density SNP array allelokaryotyping of human acute lymphoblastic leukemia (ALL) xenografts in immunodeficient mice reveals genomic changes upon in vivo induction of chemoresistance', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209701802253&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smith MA; Morton CL; Carol H; Gorlick RG; Kang MH; Keir ST; Kolb EA; Lock RB; Maris JM; Houghton PJ, 2009, 'Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606606513&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smith MA; Morton CL; Carol H; Gorlick RG; Kang MH; Keir ST; Kolb EA; Lock RB; Maris JM; Houghton PJ, 2009, 'Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A.', in J Clin Oncol, United States, Vol. 27, pp. 10015, United States, http://www.ncbi.nlm.nih.gov/pubmed/27962529

Houghton PJ; Morton CL; Maris JM; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Kang MH; Smith MA, 2008, 'Pediatric Preclinical Testing Program (PPTP) evaluation of rapamycin combined with cytotoxic drugs used frequently in treatment of childhood cancer', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, SWITZERLAND, Geneva, pp. 60 - 60, presented at 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SWITZERLAND, Geneva, 21 October 2008 - 24 October 2008, http://dx.doi.org/10.1016/S1359-6349(08)72122-0

Lock R; Carol H; Houghton P; Morton C; Phelps D; Tucker C; Payne-Turner D; Zuany-Amorim C; Smith M, 2008, 'Pediatric Preclinical Testing Program (PPTP) evaluation of the anti-CD19-DM4 conjugated antibody SAR3419', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, SWITZERLAND, Geneva, pp. 61 - 61, presented at 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SWITZERLAND, Geneva, 21 October 2008 - 24 October 2008, http://dx.doi.org/10.1016/S1359-6349(08)72124-4

Smith MA; Houghton PJ; Morton CL; Maris JM; Courtright J; Carol H; Lock RB; Yang Y; Manfredi MG, 2008, 'Pediatric Preclinical Testing Program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, SWITZERLAND, Geneva, pp. 92 - 93, presented at 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SWITZERLAND, Geneva, 21 October 2008 - 24 October 2008, http://dx.doi.org/10.1016/S1359-6349(08)72220-1

Hsu A; Kerr B; Lock R; Hart D; Rice A, 2007, 'Anti-leukaemic CTL control the kinetics of leukaemic growth in the NOD-SCID mouse model', in BONE MARROW TRANSPLANTATION, NATURE PUBLISHING GROUP, FRANCE, Lyon, pp. S31 - S32, presented at 33rd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, FRANCE, Lyon, 25 March 2007 - 28 March 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000245207400083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Liaw T; Burke P; Chen X; LaVallee T; Lock RB; Kavallaris M, 2007, 'ENMD-1198 in combination with vincristine shows synergistic activity in leukemia cells and prolonged mouse survival in human leukemia xenografts', in Broze G (ed.), Blood, American Society of Hematology, USA, pp. 859 - 859, presented at 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, Georgia USA, 08 December 2007 - 11 December 2007

Liaw TTYE; Burke PPA; Chen X; LaVallee TTM; Lock R; Kavallaris M, 2007, 'ENMD-1198 in combination with vincristine shows synergistic activity in leukemia cells and prolonged mouse survival in human leukemia xenografts', in BLOOD, AMER SOC HEMATOLOGY, GA, Atlanta, pp. 263A - 263A, presented at 49th Annual Meeting of the American-Society-of-Hematology, GA, Atlanta, 08 December 2007 - 11 December 2007, http://dx.doi.org/10.1182/blood.V110.11.859.859

Lock RB; Jin L; Lee EM; Ramshaw H; Busfield S; Peoppl A; Wilkinson L; Guthridge M; Boyd AW; Gearing D; Vairo G; Lopez A; Dick J, 2007, 'CD123 (IL-3 receptor a chain) neutralization by a monoclonal antibody selectively eliminates human acute myeloid leukemic stem tells', in Broze G (ed.), Blood, American Society of Hematology, USA, pp. 161 - 161, presented at 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, Georgia USA, 08 December 2007 - 11 December 2007

Lock RB; Jin L; Lee EM; Ramshaw HS; Busfield S; Peoppl AG; Wilkinson L; Guthridge MA; Boyd A; Gearing D; Vairo G; Lopez A; Dick JE, 2007, 'CD123 (IL-3 receptor a chain) neutralization by a monoclonal antibody selectively eliminates human acute myeloid leukemic stem tells', in BLOOD, AMER SOC HEMATOLOGY, GA, Atlanta, pp. 55A - 55A, presented at 49th Annual Meeting of the American-Society-of-Hematology, GA, Atlanta, 08 December 2007 - 11 December 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000251100800162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smith MA; Maris JM; Keir ST; Lock RB; Carol H; Gorlick R; Kolb EA; Keshelava N; Reynolds CP; Morton C; Houghton PJ, 2007, 'Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043700627&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Choi S; Kwan E; Beesley A; Sutton R; Lock RB; Papa R; Marshall GM; Kees UR; Haber M; Norris MD, 2006, 'Relapse in children with acute lymphoblastic leukaemia is associated with selection of a pre-existing drug resistance subclone', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Vol. 4, pp. 81 - 81, http://dx.doi.org/10.1016/S1359-6349(06)70257-9

Hsu AK; Kerr BM; Lock RB; Hart DN; Rice AM, 2006, 'RNA transfected cord blood-derived dendritic cells generate anti-leukemic cytotoxic T lymphocytes', in BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, CARDEN JENNINGS PUBL CO LTD, HI, Honolulu, pp. 65 - 65, presented at 32nd Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, HI, Honolulu, 16 February 2006 - 20 February 2006, http://dx.doi.org/10.1016/j.bbmt.2005.11.204

Hsu AKW; Kerr BM; Lock RB; Hart DNJ; Rice AM, 2006, 'Anti-leukemic CTL generated by RNA loaded cord blood-derived dendritic cells control leukaemia in a NOD-SCID mouse model.', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, pp. 1057A - 1057A, presented at 48th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 09 December 2006 - 12 December 2006, http://dx.doi.org/10.1182/blood.V108.11.3699.3699

Houghton PJ; Maris JM; Friedman HS; Keir ST; Lock RB; Gorlick R; Kolb EA; Reynolds CP; Morton C; Smith MA, 2005, 'Evaluation of bortezomib against childhood tumor models by the pediatric preclinical testing program (PPTP)', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, pp. 8987S - 8988S, presented at 17th EORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics, PA, Philadelphia, 14 November 2005 - 18 November 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000234382700098&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hsu AKW; Kerr BM; Lock RB; Hart DNJ; Rice AM, 2005, 'Assembling the players for evaluation of anti-leukemic CTL activity in NOD-SCID mice.', in BLOOD, AMER SOC HEMATOLOGY, GA, Atlanta, pp. 226B - 226B, presented at 47th Annual Meeting of the American-Society-of-Hematology, GA, Atlanta, 10 December 2005 - 13 December 2005, http://dx.doi.org/10.1182/blood.V106.11.4586.4586

Lock RB; Davies C; Bardell J, 2005, 'Differential sensitivity of childhood acute lymphoblastic leukemia xenografts to vorinostat reflects p21WAF1/CIP1 functional status.', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, pp. 8986S - 8986S, presented at AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, PA, Philadelphia, 14 November 2005 - 18 November 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000234382700092&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lock RB; Bachmann P, 2003, 'Induction of the pro-apoptotic Bcl-2 family member, Bim, is critical for glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells.', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MASSACHUSETTS, BOSTON, pp. 6211S - 6211S, presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, MASSACHUSETTS, BOSTON, 17 November 2003 - 21 November 2003, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000187467300581&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lock RB; Liem N, 2003, 'Specific down regulatlon of stathmin in childhood acute leukemiaxenografts selected for vincristine resistance in vivo', in Blood, American Society of Hematology, SAN DIEGO, CALIFORNIA, pp. 591A - 591A, presented at 45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 06 December 2003 - 09 December 2003, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000186536702177&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Bendall LJ; Khan NI; Bonnet C; Lock RB; Nilsson S; Bradstock KF; Gottlieb DJ, 2002, 'CD44v6 expression results in increased aggressiveness of acute lymphoblastic leukemia in NOD/SCID mice.', in BLOOD, AMER SOC HEMATOLOGY, PENNSYLVANIA, PHILADELPHIA, pp. 757A - 757A, presented at 44th Annual Meeting of the American-Society-of-Hematology, PENNSYLVANIA, PHILADELPHIA, 06 December 2002 - 10 December 2002, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000179184702999&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lock RB; Liem N; Tajbakhsh M; Milross CG; Xue CY; Haber M; Norris MD; Marshall GM; Rice AM, 2001, 'Novel biological characteristics and disparate vincristine responses of primary childhood acute lymphoblastic leukemia cells engrafted into non-obese diabetic/severe combined immunodeficient mice.', in BLOOD, AMER SOC HEMATOLOGY, pp. 309A - 310A, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000172134101312&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lock R; Farnsworth M; Wood J; Milross C; Collins C; Rice A, 2000, 'Development of an in vivo model for the testing of novel antileukemic agents.', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, pp. 4498S - 4498S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000165409000119&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Eastman A, 1986, 'AACR Special Conference in Cancer Research', in Cancer Research, pp. 2812 - 2818

Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Ritenour LE; Modi A; Farrel A; Way GP; Kendsersky NM; Patel K; Lopez G; Vaksman Z; Mayoh C; Nance J; Mccoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni H; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Morozova Vaske O; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li X-N; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM, Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design, http://dx.doi.org/10.2139/ssrn.3377367

Wakefield C; Doolan EL; Fardell JE; Signorelli C; Veronica QF; Tucker KM; Patenaude AF; Marshall GM; Lock RB; Georgiou G; Cohn RJ, The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care, http://dx.doi.org/10.2139/ssrn.3260779